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therapeutics and fields ranging from oncology to neurology. In addition, a critical, recent technological
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striking changes in the dorsolateral prefrontal cortex of affected human brains. Interestingly, the nature of
these changes differs between mitochondrial and nuclear tRNAs, implicating an association between
Alzheimer's disease and perturbation of mitochondrial function. In addition, by combining known genetic
factors of AD with genes that are differentially expressed and targets of regulatory RNAs that are differentially
expressed, I construct a network of genes that are potentially relevant to the pathogenesis of the disease. By
combining genetics data with novel results from the study of non-coding RNAs, we can further elucidate the
molecular mechanisms that underly Alzheimer's disease pathogenesis.
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ABSTRACT 
 
METHODS IN AND APPLICATIONS OF THE SEQUENCING OF SHORT NON-CODING RNAS 
Paul Ryvkin 
Li-San Wang 
 
Short non-coding RNAs are important for all domains of life. With the advent of modern molecular 
biology their applicability to medicine has become apparent in settings ranging from diagonistic 
biomarkers to therapeutics and fields ranging from oncology to neurology. In addition, a critical, 
recent technological development is high-throughput sequencing of nucleic acids. The 
convergence of modern biotechnology with developments in RNA biology presents opportunities 
in both basic research and medical settings. Here I present two novel methods for leveraging 
high-throughput sequencing in the study of short non-coding RNAs, as well as a study in which 
they are applied to Alzheimer’s Disease (AD). The computational methods presented here 
include High-throughput Annotation of Modified Ribonucleotides (HAMR), which enables 
researchers to detect post-transcriptional covalent modifications to RNAs in a high-throughput 
manner. In addition, I describe Classification of RNAs by Analysis of Length (CoRAL), a 
computational method that allows researchers to characterize the pathways responsible for short 
non-coding RNA biogenesis. Lastly, I present an application of the study of non-coding RNAs to 
Alzheimer’s disease. When applied to the study of AD, it is apparent that several classes of non-
coding RNAs, particularly tRNAs and tRNA fragments, show striking changes in the dorsolateral 
prefrontal cortex of affected human brains. Interestingly, the nature of these changes differs 
between mitochondrial and nuclear tRNAs, implicating an association between Alzheimer’s 
disease and perturbation of mitochondrial function. In addition, by combining known genetic 
factors of AD with genes that are differentially expressed and targets of regulatory RNAs that are 
differentially expressed, I construct a network of genes that are potentially relevant to the 
pathogenesis of the disease. By combining genetics data with novel results from the study of non-
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coding RNAs, we can further elucidate the molecular mechanisms that underly Alzheimer’s 
disease pathogenesis. 
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1.  Introduction 
1.1. RNA Biology 
1.1.1. The Central “Dogma” 
 
The central hypothesis (or as Francis Crick infamously and erroneously coined it, the ―central 
dogma‖) [35,36] of molecular biology outlines the relationship between three important types of 
organic molecules: DNA (deoxyribonucleic acids), RNA (ribonucleic acids), and proteins (Figure 
1.1). The totality of each type of molecule in the cell is referred to as the genome, the 
transcriptome, and the proteome, respectively. Under this framework, information flows from DNA 
to RNA and then to proteins; DNA serves as a template for transcription of RNA, which in turn 
serves as a template for translation into protein. Proteins form enzymes which carry out a range 
of functions throughout the cell and are generally responsible for phenotype, or the appearance 
and behavior of the organism. While we now know that there are many exceptions to this view  
[12,91,112,140,150] (Figure 1.2), it is a useful start for describing molecular biology. 
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Figure 1.1 – The central hypothesis of molecular biology. 
 
 
Figure 1.2 – The central hypothesis revised. 
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DNA can be considered a fixed information storage medium for the cell. Exceptions to 
this picture of DNA include the entire field of epigenetics which seeks to describe dynamic 
modifications to DNA, as well as the study of the processes of DNA replication and repair. In 
general, however, DNA serves only as a template and is not responsible for catalyzing other 
types of reactions. 
RNA, in contrast, exists in a constant state of flux via creation (transcription from DNA) 
and destruction (finely controlled turnover by enzymes). Similarly, proteins, which comprise 
enzymes, exist in a constant state of flux. For many years, proteins alone were considered to be 
the workhorse of the cell – after all, they catalyze nearly all of the reactions necessary to support 
life while DNA and RNA ―merely‖ store information. However, with the discovery of catalytic RNAs 
(ribozymes) [27,69,94], these molecules are now appreciated as more than simple ―messengers‖ 
between DNA and proteins. It is especially difficult to write off RNAs since the machinery that 
translates RNA into protein (the ribosome) is itself made up of RNA; indeed, it has been shown 
that the RNA (not the protein) component of this machinery is responsible for its activity [120]. 
RNA is therefore a key component of the cellular machinery and not simply a transitory 
messenger. 
Like the other ubiquitous organic polymers central to life (DNA and proteins), RNA 
primarily stores information by way of its sequence. While DNA is a polymer of the 
deoxyribonucleotides deoxyadenosine (dA), deoxycytidine (dC), deoxyguanosine (dG), and 
deoxythymidine (dT), RNA is a polymer of the ribonucleotides adenosine (A), cytidine (C), 
guanosine (G), and uridine (U) [6]. The key differences are RNA’s inclusion of a hydroxyl group 
where DNA is missing one, the substitution of uridine for thymidine, and RNA’s propensity to exist 
in a greater variety of structural forms. Analogous to DNA, it is the sequential order of the 
ribonucleotides that form the primary information content of RNA. Another form of information 
stored by RNA is its structure; RNAs are prone to fold into particular geometries which can be 
important for their catalytic functions [123,127] (Figure 1.3). The primary structure of an RNA is 
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its sequence. Its secondary structure is a graph whose nodes are nucleotides and whose edges 
represent Watson-Crick and wobble-pairing interactions between pairs of these nucleotides. Its 
tertiary structure describes long-range interactions between its base-paired and/or unpaired 
sections. Finally, the quaternary structure of an RNA models its interactions with other molecules. 
In addition to the folding geometry of the RNA, a third form of information is the presence of non-
canonical nucleotides formed by covalent modification of the standard four [3,4,37,166,169] – in 
Chapter 3 I present a method for detecting these non-canonical nucleotides. 
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Figure 1.3 – The structure of RNAs. 
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1.1.2. Protein-coding RNAs 
 
RNAs can be broadly categorized into two groups: those that code for proteins (coding RNAs) 
and those that do not (non-coding, or ncRNAs). The only extant class of coding RNAs is 
messenger RNAs (mRNAs) – however, not all mRNAs code for proteins. In higher eukaryotes, 
mRNAs are transcribed by the enzyme RNA polymerase II and undergo a sophisticated 
maturation process from the original mRNA transcript [117]: they can be spliced into various 
isoforms [65], they are capped by a special chemical structure on the 5’ end [133], they are 
polyadenylated on the 3’ end, and their sequence can be dynamically changed [139] (RNA 
editing) and chemically modified (RNA modification). The terms 5’ and 3’ correspond to the 
exposed atom of the ribose sugar in the ribonucleotide – generally a 5’ triphosphate on one end 
and a 3’ hydroxyl group on the other end. Since mRNAs are translated into proteins from 5’ to 3’, 
these are conventionally depicted as the left and right ends of the molecule, respectively. In 
eukaryotic splicing, multiple alternative forms of an RNA transcript are generated when the 
cellular splicing machinery removes sections called introns and concatenates together sections 
designated as exons, which usually contain the coding portion of the transcript (i.e., the sequence 
that will determine the translated protein). Thus one gene may produce many distinct mRNAs 
with varying sequences which are then translated into proteins with a variety of functions. 
Capping, in eukaryotic organisms, refers to the addition of the ribonucleotide N7-methylguanosine 
(m
7
G) to the 5’ carbon of the mRNA via an unconventional 5’-5’ triphosphate linkage. This cap 
serves to stabilize the mRNA and promote its export from the nucleus. Polyadenylation is a 
process whereby a homopoylmer of adenosines is sequentially added to the 3’ end of the mRNA. 
Among other functions, this poly(A) ―tail‖ regulates enzymatic degradation of the mRNA from the 
3’ end. Nearly all eukaryotic mRNAs are polyadenylated with the notable exception of the histone 
genes, where the 3’ terminus is designated by a small stem-loop RNA structure. The process of 
RNA editing generally consists of post-transcriptional changes in the sequence of an RNA. In the 
case of eukaryotic mRNAs, this is usually a deamination of adenosine to inosine or deamination 
of cytidine to uridine [85]. Inosine has similar base-pairing properties to guanosine, but overall it is 
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far less specific in its base-pairing specificity. These changes to an mRNA’s sequence can affect 
its alternative splicing, stability, and even the eventual protein sequence that is coded. Other 
types of changes to an RNA’s sequence, which always produce non-canonical nucleotides, are 
termed RNA modifications. Examples of RNA modifications are the methylation of guanosine at 
the carbon 2 amine (producing N2-methylguanosine or m
2
G) and the isomerization of uridine into 
its C-glycoside pseudouridine (Ψ). These types of modifications are believed to be rare in protein-
coding mRNAs, but the search for them is an active field of research. So far, it seems that the 
non-canonical nucleotides 5-methylcytidine (m
5
C) and N6-methyladenosine (m
6
A) can be found 
in mRNAs transcriptome-wide [115]. Furthermore, the recent discovery that a gene whose 
variants are found to be associated with obesity in humans, FTO, is an adenosine N6-
methyltransferase suggests that these modifications may play a very important role in human 
disease [57,84]. 
 
1.1.3. Non-coding RNAs 
While protein-coding mRNAs are important for deciding the sequences of proteins, the most 
abundant RNAs in the cell by far are non-coding RNAs; ribosomal RNA (rRNA) can make up over 
80% of all the RNA in mammalian cells. The next most abundant class of non-coding RNAs, 
transfer RNAs (tRNAs), can make up another 10%. Not only are non-coding RNAs the most 
abundant RNAs in the cell, they are also the most evolutionarily conserved: all cellular life on 
earth relies on ribosomes, and thus ribosomal RNA, and the similarity of its sequence among 
disparate organisms is great enough for it to act a universal phylogenetic character [128]. The 
universality of ribosomal RNA, combined with its sufficiency for ribosomal function is a central 
piece of evidence supporting the hotly-debated ―RNA world‖ hypothesis which claims that the use 
of RNA as an information storage medium preceded DNA’s on Earth [26]. 
Aside from their lack of protein-coding capacity, there are many fundamental differences 
between coding and non-coding RNAs, ranging from how they encode information to how they 
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are processed. For example, while the non-canonical nucleotide modifications described in 
Section 1.1.2 are thought to be rare in mRNAs, they are ubiquitous in non-coding RNAs. The 
most abundant non-canonical nucleotide in the cell, pseudouridine, is commonly found in rRNA 
and tRNA [73]. 
Unlike protein-coding mRNAs, there is great diversity in the non-coding RNA population 
[83,114] (Table 1.1). Unfortunately, producing a consistent nomenclature of non-coding RNAs is 
a difficult task, and currently it proceeds in an ad hoc manner publication by publication. For 
example, while some classes of RNA are defined by their location in the cell, others are defined 
by the genomic neighborhood of their DNA template. An initial useful subdivision of non-coding 
RNAs is by their size: generally ncRNAs shorter than around 50 nucleotides (nt) are considered 
short non-coding RNAs, or ―small RNAs,‖ while longer ones are referred to as long non-coding 
RNAs (lncRNAs). Section 1.1.4  describes the many types of short non-coding RNAs, while this 
section focuses on the longer ones. 
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Table 1.1 – A compendium of non-coding RNAs found in animals. 
Abbreviation Name Biological role Example(s) 
rRNA Ribosomal RNA Translation 5S rRNA 
tRNA Transfer RNA Translation tRNA
Met
CAU 
snoRNA Small nucleolar RNA RNA modification SNORD115 
snRNA Small nuclear RNA mRNA splicing U1 
scRNA Small cytoplasmic RNA Various hY1 
srpRNA Signal recognition 
particle RNA 
Protein localization  
lincRNA Long intergenic non-
coding RNA 
Various XIST, TSIX, 
MALAT1 
miRNA Micro RNA mRNA silencing let-7 
piRNA Piwi-interacting RNA Transposon silencing piR-53941 
tRF tRNA fragment Unknown tRNA
Met
CAU 5’ half 
paRNA Promoter-associated 
RNA 
Unknown EF1a promoter 
vtRNA Vault RNA Unknown; drug resistance VTRNA1-1 
aRNA Antisense RNA mRNA regulation BACE1-AS 
natRNA Natural antisense 
transcript RNA 
Unknown HAS2-AS1 
- Transposable elements Self replication SINEs and LINEs 
Hammerhead Hammerhead ribozyme mRNA regulation C10orf118 
TERC Telomerase RNA 
component 
Telomere extension TERC 
RNase P Ribonuclease P RNA 
component 
Cleavage of pre-tRNAs RPPH1 
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Ribosomal RNA is largely transcribed by RNA polymerase I and is central to an organelle 
within the cell called the ribosome [122]. Ribosomes are responsible for translating mRNAs into 
proteins. In eukaryotes the ribosome is made up of a small subunit (SSU) and large subunit 
(LSU). In the human genome ribosomal RNA exists in many copies (as rDNA), and often in long 
tandem arrays, which have long presented an obstacle to assembly of the human genome due to 
their repetitive nature. Ribosomal RNA maturation takes place in the nucleolus, a small 
substructure of the nucleus, where it is spliced and modified in myriad ways by other RNAs and 
ribonucleoprotein (RNP) complexes. Importantly, it is the structure of the rRNA that is responsible 
for its function, not necessarily its sequence; structure-over-sequence is a common theme among 
ncRNAs. 
The next most abundant class of ncRNA is transfer RNA [127]. Transfer RNAs are 
transcribed by RNA polymerase III and tend to be around 70 nt in length; they fold into a 
distinctive ―cloverleaf‖ secondary structure with an L-shaped tertiary structure. Like rRNA, the 
DNA genes from which they are transcribed (tDNA) exist with high copy number in mammalian 
genomes [13]. The function of tRNA is to act as an intermediary between mRNA and the 
ribosome. The acceptor arm of a tRNA is covalently bonded to a specific amino acid by a highly 
conserved family of proteins called tRNA aminoacyl synthases. The anticodon loop of a tRNA 
contains a three-nucleotide sequence called the ―anticodon.‖ When an mRNA is being translated 
by a ribosome, the appropriate tRNA associates with the mRNA’s current codon (three-letter code 
associated with an amino acid) by way of sequence complementarity. Thus a tRNA provides a 
link between particular codon sequences and particular amino acids, giving rise to the genetic 
code (Table 1.2). In tRNAs, both the structure and sequence are of critical importance – their 
structure allows for the appropriate interaction with the ribosome while their sequence provides 
specificity for particular codons. Notably, there are fewer tRNA anticodons encoded in the 
genome than there are complementary codons in the genetic code. This is because one tRNA 
can bind to multiple codons by way of covalent RNA modifications in the anticodon loop, yielding 
nucleotides with degenerate base pairing properties (e.g., inosine). Structural perturbations thus 
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induced adjacent to the anticodon can also alter the specificity of the codon-binding. Like mRNAs 
and rRNAs, tRNAs can also have introns that are spliced out [1]. 
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Table 1.2 – The eukaryotic nuclear genetic code. 
RNA Codon Amino acid  RNA Codon Amino acid 
UUA  
 
 
Serine (Ser) 
 CGU  
 
 
Arginine (Arg) 
UUG  CGC 
UCU  CGA 
UCC  CGG 
AGU  AGA 
AGC  AGG 
UUA  
 
 
Leucine (Leu) 
 GGU  
 
Glycine (Gly) 
UUG  GGC 
CUU  GGA 
CUC  GGG 
CUA  AUU  
Isoleucine (Ile) CUG  AUC 
GUU  
 
Valine (Val) 
 AUA 
GUC  UUU Phenylalanine (Phe) 
GUA  UUC 
GUG  CAU  
Histidine (His) CCU  
 
Proline (Pro) 
 CAC 
CCC  CAA  
Glutamine (Gln) CCA  CAG 
CCG  AAU  
Asparagine (Asn) ACU  
 
Threonine (Thr) 
 AAC 
ACC  AAA  
Lysine (Lys) ACA  AAG 
ACG  GAU  
Aspartic acid (Asp) GCU  
 
Alanine (Ala) 
 GAC 
GCC  GAA  
Glutamic acid (Glu) GCA  GAG 
GCG  UAA  
Stop codon UGU  
Cysteine (Cys) 
 UAG 
UGC  UGA 
UAU  
Tyrosine (Tyr) 
 UGG Tryptophan (Trp) 
UAC  AUG Methionine (Met) 
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Small nucleolar RNAs (snoRNAs) are, as their name suggests, non-coding RNAs that are 
generally localized to the nucleolus (but also Cajal bodies) [49]. There are three main subclasses 
of small nucleolar RNAs, each having a different set of structural and sequence motifs: C/D box, 
H/ACA box, and small Cajal body-specific (scaRNA). The main function of snoRNAs is to guide 
covalent modification of other RNAs, ranging from rRNA to small nuclear RNAs (snRNAs), via 
small nucleolar ribonucleoprotein (snoRNP) complexes. In general, C/D box snoRNAs guide 
methylation of RNAs while H/ACA box snoRNAs guide pseudouridylation of RNAs. One notable 
exception is the C/D box snoRNA SNORD115, which has complementarity to the serotonin 2 C 
receptor mRNA and alters its splicing [88]. 
Small nuclear RNAs (snRNAs) largely comprise the RNA component of the spliceosome; 
that is, they make up the machinery responsible for splicing of RNAs [51,118,154]. As their name 
suggests, they are largely localized to the nucleus. There are several families of snRNAs with 
names such as U1, U2, and so on. In conjunction with proteins they form small nuclear 
ribonucleoprotein (snRNP) complexes, which form the spliceosome. As with the other ncRNA 
types described, their genes exist in high copy number scattered throughout mammalian 
genomes [107]. 
A somewhat mysterious and only recently described class of non-coding RNAs is that of 
long intergenic non-coding RNAs (lincRNAs) [24,87]. lincRNAs look very similar to mRNAs – they 
are transcribed by RNA polymerase II and tend to be polyadenylated and spliced – but they do 
not code for proteins and often localize to the nucleus rather than the cytoplasm. While some 
notable examples of lincRNAs, such as Xist [32] and MALAT1 [82] have been well known for 
quite some time, the recent application of high-throughput RNA-sequencing has illuminated many 
more lincRNAs with varying levels of abundance and tissue specificity. Their function and 
biological relevance are largely unknown. 
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1.1.4. Short non-coding RNAs (small RNAs) 
Short non-coding RNAs, or small RNAs (smRNAs), play an important role in higher eukaryotic 
transcriptomes. RNAs that are considered small RNAs tend to be less than 45 nt in length, 
although there is no standard cutoff for the definition. They are almost always the product of 
processing a longer transcript rather than being independently transcribed directly from the 
genome. The pathways responsible for generation of smRNAs generally consist of a number of 
proteins and ribonucleoprotein complexes that process the precursor transcript in tandem and in 
parallel. These pathways tend not to be as conserved across evolutionary distances as some 
highly conserved proteins. Plants and animals, for example, have rather distinct smRNA 
pathways that behave in quite different ways as a whole. 
 The best characterized class of smRNA to date is the microRNA [145]. MicroRNAs are a 
particular subtype of small interfering RNA (siRNA) [55]. Small interfering RNAs were first 
described by Craig C. Mello, Andrew Fire, and others in their 1998 Nature article, for which Mello 
and Fire won a Nobel Prize in 2006. They are short (~21 nt) double-stranded RNAs which 
promote gene silencing through a variety of methods – usually by either catalyzing degradation of 
an mRNA transcript or inhibition of translation of an mRNA into its concomitant protein. They 
target specific mRNAs by nature of having sequence complementarity (full or partial) to a 
particular site on the mRNA, usually in its 3’ untranslated region (3’ UTR). The distinguishing 
features of microRNAs are that they tend to be processed either from larger transcripts called 
primary miRNAs (pri-miRNAs) or from introns that have been spliced out of pre-mRNAs (so called 
mirtrons). In animals, the processing of pri-miRNAs into pre-miRNAs is accomplished in the 
nucleus by the microprocessor complex, a protein complex that includes the Drosha and 
Pasha/DGCR8 proteins; this complex recognizes hairpins on pri-miRNAs and cleaves them out, 
creating pre-miRNAs. Mirtrons bypass this processing as they originate from introns and not pri-
miRNA transcripts. The resulting pre-miRNA, which generally consists of a stem and a loop 
structure, is then exported to the cytoplasm by the protein Exportin-5. In the cytoplasm, an 
endonuclease called Dicer further processes the stem-loop pre-miRNA into a mature 
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miRNA:miRNA* duplex by cleaving out the loop and a part of the stem. Each strand of the duplex 
forms a distinct single-stranded mature miRNA with full or near-complementarity between the 
two. The convention for which one is dubbed the ―star‖ miRNA is usually set by their order of 
discovery, the method by which the miRNA was discovered, and the relative expression levels of 
each miRNA strand in the tissue in which it was discovered. The resulting mature miRNAs tend to 
be about 22nt long in animals. It is these mature miRNAs, in conjunction with the RNA-induced 
silencing complex (RISC), which form a regulatory ribonucleoprotein complex that carries out 
silencing activity on mRNAs. The class of protein that is central to RISC’s silencing activity is the 
Argonaute family. They are responsible for guiding the miRNA to its target mRNA. The miRNA-
RISC (miRISC) then silences the mRNA transcript either by inhibiting translation into protein by 
the ribosome or degradation of the mRNA via cleavage. 
Another type of small RNA found in animals is the Piwi-interacting RNA (piRNA), named 
after the Piwi class of proteins, a subclass of the Argonaute family [64,81,132,137]. Unlike 
miRNAs, piRNAs tend to be significantly longer (26-32 nt versus 22nt) and also tend to have a 
uridine on their 5’ end. The process by which they are generated is not yet fully clear. However, 
their functional role has been partially elucidated: they are involved in the silencing of ―selfish‖ 
genetic elements known as transposons as well as in the placement of epigenetic marks on 
chromatin. They are also highly active in mammalian testes and are required for mammalian 
spermatogenesis. 
There are a variety of other types of small non-coding RNAs, and in the literature they are 
generally labeled by their precursor RNA. Small RNAs can be produced from any type of 
precursor, ranging from protein-coding mRNA to non-coding RNA types such as rRNA, tRNA, 
snRNA, and snoRNA. There is evidence that some of these small RNAs are processed like and 
behave like microRNAs: they are produced by cleavage of stem-loop structures by the Dicer 
protein and go on to have regulatory effects on mRNAs [9,18,103,126]. The fact that they 
originate from precursor transcripts other than pri-miRNAs does not preclude them from behaving 
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like miRNAs. However, the vast majority of non-miRNA small RNAs that are commonly found in 
small RNA-seq datasets, for example, are entirely uncharacterized other than their annotated 
precursor transcript. For example, tRNA-derived smRNAs (known as tRFs, or tRNA fragments) 
[99], are thought to be the result of a combination of endolytic cleavage under stress response 
conditions and non-specific cleavage by Dicer – but whether they are a simply non-specific 
byproduct of smRNA processing pathways or go on to have functional regulatory roles has yet to 
be determined. In Chapter 3 I present a quantitative method that can help researchers 
characterize these largely unstudied populations of small RNAs. 
 
1.2. Measuring the transcriptome 
The advent of high-throughput sequencing (HTS), the most common subtype of which is shotgun 
sequencing, has heralded in a new age of computational biology. In current-generation shotgun 
sequencing, DNA (or RNA) is fragmented into smaller pieces and then a machine produces 
―reads‖ by reading the sequence of these fragments from either one end (single-end sequencing) 
or both ends (paired-end sequencing). While the sequencing of genomes (DNA-seq) has gained 
recent attention, researchers are starting to see the value in applying these technologies to the 
sequencing of RNA (RNA-seq) [124] (Figure 1.4). In DNA-seq, researchers seek genetic variants 
that are uncommon, as well as types of variants that are difficult to detect with genotyping 
methods. This same level of sensitivity can be applied to RNA, where the goal is to not only 
determine the sequences of RNA transcripts, but also to infer changes in their abundance and 
alternative splicing between experimental conditions or in disease states. In this dissertation I 
present alternative facets of the transcriptome that can be measured using this data, but have not 
yet been fully explored (Chapters 2 and 3). While the clinical applications of RNA-seq have yet to 
be fully realized, it can already be used for biomarker discovery and in the generation of target 
hypotheses for, e.g., drug discovery. Traditional RNA-sequencing focuses solely on 
polyadenylated messenger RNAs, perturbations of which are more amenable to interpretation 
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when the function of the coded protein is known. However, alternative forms of RNA-sequencing, 
such as those that I present in this dissertation, are just as important in assaying the impact of the 
full (coding and non-coding) transcriptome (Chapter 4). Examples of alternate forms of RNA-
sequencing are: Ribosomal RNA-depleted RNA-seq (rRNA(-) RNA-seq) [30], small RNA-seq 
(smRNA-seq) [95], cross-linking immunoprecipitation-high-throughput sequencing (CLIP-seq)  
[105], Bisulfite RNA-seq [143], methylated RNA immuniprecipitation RNA-seq (MeRIP-seq) [115], 
double-stranded RNA-seq (dsRNA-seq) [172], single-stranded RNA-seq (ssRNA-seq), and 
degradome-seq (PARE, GMUCT) [2,63,66,159]. 
 
 
Figure 1.4 – Strand-specific polyA(+) RNA-sequencing. 
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In rRNA(-)-seq, the goal is similar to that in regular polyA(+) seq – measure abundance of 
and detect alternative splicing of transcripts. However, instead of limiting the experiment to only 
those RNAs with poly(A) tails, depleting ribosomal RNA allows one to assay a wider range of 
transcripts. One downside, however, is that the presence of highly abundant non-coding, polyA(-) 
RNAs can reduce the dynamic range of the estimated read counts. Although with recent 
increases in sequencing depth capabilities, this disadvantage has grown considerably less 
important. In Chapter 4 I describe an application of rRNA(-)-seq to a study of the differences in 
non-coding RNAs in the Alzheimer’s disease brain. 
Small RNA-seq is similar to rRNA(-) seq in that its intended purpose is to infer the 
abundance of non-coding RNAs. However, the method focuses on a subgroup of non-coding 
RNAs that are shorter than a particular length; the desired range for sequenced RNAs is usually 
15-45nt. In small RNA-seq, usually the rRNA depletion is forgone and instead an additional size-
fractionation step is added: the shorter fraction of RNAs is selected by polyacrylamide gel 
electrophoresis (PAGE) and subsequent gel extraction. Again, this type of RNA-sequencing is 
applied to Alzheimer’s disease in Chapter 4. 
While the previously described methods are used to assay the abundance and splicing 
changes in RNAs, there are other aspects of the transcriptome that can be measured. For 
example, in CLIP-seq, the goal is to elucidate the binding-specificity of an RNA-binding protein. In 
short, the RNA and all its bound proteins are cross-linked, and an antibody specific to one protein 
is used to pull-down a fraction of RNA that is enriched for the protein of interest. Then after 
fragmentation and removal of the proteins, RNA-sequencing is performed on the enriched 
fraction. After mapping these reads back to the genome, one can infer all of the sites in the 
transcriptome where the protein has some binding affinity. This can be used to determine general 
rules for the specificity of this particular protein by performing de novo sequence- or structural- 
motif searches within the enriched sequences. The procedure is analogous to chromatin-
immunoprecipitation sequencing (ChIP-seq), where the goal is to find binding sites of chromatin-
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binding proteins. Among other studies, CLIP-seq has been applied to the study of an RNA-
binding protein called TDP-43 which is implicated in the pathogenesis of neurodegenerative 
disorders such as amyelotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).  
CLIP-seq is also useful for finding in vivo sites of microRNA-mRNA binding by using an antibody 
specific to proteins in the miRNA silencing machinery; such studies are extremely important for 
elucidating regulatory targets of short RNAs such as microRNAs. 
Another example of a DNA-sequencing protocol that has been adapted to RNA-seq is 
that of bisulfite sequencing. The goal in bisulfite RNA-seq is to detect sites in the transcriptome 
where a cytidine has been replaced by a 5-methylcytidine (m
5
C) – that is, one is searching for a 
particular RNA modification in all RNAs. The protocol consists of treating the RNA with bisulfite 
before sequencing. Treatment with bisulfite deaminates cytosine to uracil, but 5-methylcytidine 
resists this conversion. After sequencing, one can detect conversion at cytidines and infer that the 
cytidines that are not converted into uridine must be methylated at the N5 position. 
Computationally, this presents issues as the conversions induce mismatches between the RNA 
sequences and the genomic sequence, which complicates the process of mapping these 
sequences back to the genome. However, specific alignment methods have been developed to 
mitigate this particular issue. 
An alternative to bisulfite sequencing is another method called MeRIP-seq. Here, instead 
of using bisulfite to produce a signal at unmodified cytidines, one instead uses an m
5
C-specific 
antibody to immunoprecipitate m
5
C-enriched RNA. By sequencing this fraction one can infer that 
enriched sequences relative to a non-specific immunoprecipitation are likely to have m
5
C sites. In 
addition, this method can be applied to any modification rather than just m
5
C. An advantage over 
bisulfite RNA-seq is that it does not induce mismatches in the RNA sequences; a disadvantage is 
that it may lack nucleotide-by-nucleotide resolution of the specific sites that are methylated. 
Another facet of the transcriptome that is a very active research area is RNA structure 
prediction. Historically, structural prediction of biomolecules such as RNA has been a laborious 
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and expensive low-throughput process. Additionally, in silico predictions based on annotated 
sequences alone have limited accuracy. Now high-throughput RNA-sequencing, in conjunction 
with biochemical methods, has allowed researchers to predict RNA structures transcriptome-
wide. There are several methods for accomplishing this, but they largely rely on similar 
biochemical treatments: the differences lie in the algorithms used to infer structure from 
sequencing data. Briefly, RNA is digested by a structure-specific RNAse enzyme and the 
remaining undigested RNA is sequenced. When the desired fraction is that of double-stranded 
RNA (dsRNA), the RNA is treated with an ssRNAse (single-stranded RNAse). Similarly, when 
single-stranded RNA (ssRNA) is desired, the RNA is treated with a dsRNAse. By sequencing 
each of these types of libraries in parallel and using computational methods to infer base-pairing 
probabilities, one can begin to infer RNA secondary structure transcriptome-wide.  
Another variant on RNA-seq that is a high-throughput extension of existing low-
throughput methods is degradeome sequencing. Degradeome sequencing is a high-throughput 
version of 5’ RACE (rapid amplification of cDNA ends). The degradome is the fraction of RNA 
resulting from regulatory cleavage of transcripts – these transcripts are silenced by particular 
types of cleavage. These cleavage events leave particular biochemical marks on the 5’ ends of 
the resulting fragments – in particular, the lack of the 5’ cap of the original transcript. By selecting 
for these types of fragments with biochemical methods, one can sequence such fragments and 
infer sites where cleavages like this have occurred. This method is largely used in plant 
transcriptomes, where short regulatory RNAs such as microRNAs carry out their silencing activity 
largely by catalyzing endolytic cleavage of the target transcript. In doing so, one can find in vivo 
target sites of these regulatory RNAs. 
 
1.3. Alzheimer’s Disease 
Alzheimer’s disease (AD), the most common form of dementia, was discovered by the German 
neuropathologist Alois Alzheimer in 1906 [20]. As of 2013, it is the most expensive disease in the 
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US; its immense societal burden is estimated at $157-$215 billion per year [173]. The FDA 
currently approves of four drugs for its treatment, all of which are cholinesterase inhibitors, and 
none of which are particularly effective at treating the disease. While its prevalence increases 
drastically with age (the risk doubles every 5 years after age 65), we still do not know what 
fundamentally causes it. Also, while it is estimated to be around 70% heritable, the genetics of AD 
have yet to be fully elucidated [8]. 
Alzheimer’s disease is clinically characterized by progressive memory loss, cognitive 
impairment, and behavioral changes. The hallmarks of its neuropathology are structures known 
as senile plaques and neurofibrillary tangles. Senile plaques are extracellular protein aggregates 
consisting mainly of the pepide amyloid beta (Aβ), whose precursor protein is encoded by the 
gene APP (amyloid precursor protein), and whose function is yet unclear. The neurofibrillary 
tangles are composed of the hyperphosphorylated protein tau (gene: MAPT), which normally 
associates with microtubules, structures that maintain the internal structure and morphology of 
cells. 
Broadly, AD cases can be broadly classified into two categories based on their genetic 
underpinning (familial or sporadic) and also by the age of onset (early or late). The familial form of 
the disease is almost always caused by autosomal dominant mutations in a small number of 
genes related to production of the Aβ peptide: presenilins 1 and 2, which help process APP, and 
APP itself. The onset of the disease when it is familial (before 65) tends to be much earlier than 
when it is LOAD. Familial cases, however, are extremely rare: they only account for 0.5% to 2.5% 
of all AD cases. The vast remainder of AD cases are of unknown genetic etiology, although 
several risk factors have been identified by recent genome-wide association studies (GWAS) 
[14,79,119]. What these studies have shown is that the largest genetic risk factor for sporadic AD 
by far is apolipoprotein E (ApoE) on chromosome 19, and alleles in a small number of other 
genes confer additional risk (Table 1.3). It is not yet fully understood what roles are played by 
these genes in the pathogenesis of AD, and functional studies of them are a very active area of 
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research. It is hoped that these studies will lead to earlier and more accurate diagnosis of AD and 
ultimately to treatments for the disease. In Chapter 4 I integrate these known genetic factors with 
RNA-sequencing data in order to increase the impact of correlative functional data by connecting 
them to causative genetics data. 
Table 1.3 – Genes implicated in LOAD by genome-wide association in Caucasian populations. 
Gene 
symbol 
Chromosome Gene name 
ApoE 19 Apolipoprotein E 
TREM2 6 Triggering receptor expressed on myeloid cells 2 
TOMM40 19   Translocase of outer mitochondrial membrane 40 
homolog (yeast) 
BIN1 2 Briding integrator 1 
CLU 8 Clusterin 
ABCA7 
 
19 ATP-binding cassette sub-family A member 7 
CR1 1 Erythrocyte complement receptor 1 
PICALM 
 
11 Phosphatidylinositol binding clathrin assembly protein 
MS4A6A 
 
11 Membrane-spanning 4-domains, subfamily A 
CD33 
 
19 Myeloid cell surface antigen CD33 
CD2AP 
 
6 CD2-associated protein 
EPHA1 7 Ephrin type-A receptor 1 
 
1.4. Outline of dissertation 
In Chapter 2 I present a computational method that, in conjunction with one of many types of 
RNA-sequencing methods, can be used to detect modified ribunocleotides transcriptome-wide. 
The method can be considered a high-throughput generalization of already-existing low-
throughput methods that capitalizes on the availability of modern RNA-sequencing technology. In 
addition to detecting modified nucleotides, it can also differentiate between different types of RNA 
modifications. 
 In Chapter 3 I describe a method for characterizing and classifying many different kinds 
of non-coding RNAs using small RNA-sequencing data. The key innovation of this method is that 
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it digests RNA-sequencing into biologically relevant features, rather than black box-style features 
that can hinder the interpretability of the results, particularly by domain experts. Using these more 
interpretable features, which were selected based on their known relevance to RNA processing 
pathways, the software can predict with a high degree of accuracy the class of small non-coding 
RNA. In addition, this method has been validated by comparing across independent datasets 
where different tissue types were used for sequencing. 
 In Chapter 4 I present an integrative analysis of the rRNA-depleted and small RNA 
transcriptomes of the Alzheimer’s disease prefrontal cortex. I describe the genes that are 
differentially expressed and classify them by their coding potential, their known precursor RNAs, 
and their predicted and experimentally verified regulatory targets. By integrating rRNA(-) and 
small RNA transcriptome data with loci known to be genetically associated with AD, we can begin 
to build a network that connects AD risk-associated variants with functional genomics data from 
the human brain. 
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2. High-throughput Annotation of Modified 
Ribonucleotides (HAMR) 
Appeared in: Ryvkin P*, Leung YY*, Silverman IM*, Childress M, Valladares O, Dragomir I, 
Gregory BD, Wang L-S. HAMR: high-throughput annotation of modified ribonucleotides. RNA. 
2013. (*Joint first authors) 
 
2.1. Introduction 
 
Covalent post-transcriptional modifications of specific nucleotide bases in RNA molecules are 
known to be highly prevalent and physiologically important. However, their overall abundance and 
biological function are not well understood. This gap is even more surprising given that RNA  
modifications play a role in maintaining structure, catalytic activity, and cellular abundance of 
RNAs, and that all known classes of RNA molecules harbor various levels of diverse 
modifications. Additionally, the recent discovery that an RNA methyl-6 adenosine demethylase 
(FTO) is a risk gene in obesity highlights the significance of RNA modifications to human biology  
[57,62,84].  
 Methods for detecting such modifications are well established 
[23,34,68,70,76,77,115,130,170]. One such method is primer extension, which relies on the 
differential ability of reverse transcriptase to produce cDNAs with base-pair substitutions at 
positions occupied by modified nucleotides [161]. 
 
Interestingly, all high-throughput RNA 
sequencing library preparation protocols require RNA to cDNA conversion by reverse 
transcription (RT), thus we reasoned it is possible to identify sites of modified nucleotides in all 
RNAs transcriptome-wide by uncovering nucleotides with significant sequence error rates. Using 
this idea, we developed HAMR, and demonstrate that this software allows fast and reliable 
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identification of modified nucleotides at single-nucleotide resolution in all RNA classes 
transcriptome-wide through the analysis of nucleotide substitutions found in various RNA-seq 
datasets. This software will provide an important tool for future work on RNA modifications, which 
are emerging as important regulators of human biology and physiology  [43,84]. 
 
2.2. Methods 
 
2.2.1. RNA extraction and sequencing 
 
Frozen human brain tissue from four female patients without neurological pathology was obtained 
from the Center for Neurodegenerative Disease Research.  Trizol extraction was performed to 
obtain total RNA. cDNA libraries for sequencing were generated following the Illumina small RNA 
library preparation procedure. The libraries were sequenced on an Illumina GAIIx machine to 
50bp and were submitted to NCBI GEO database (GSE43335). The reads were 3' adapter-
trimmed, requiring at least 6 bp of adapter sequence with at most a 6% mismatch rate. All 
untrimmed reads and trimmed reads shorter than 14bp were discarded. The remaining reads 
were mapped to the human genome (hg19) [59] using Bowtie [97] under ―-v 2‖ mode with a 
maximum 6% mismatch rate and allowing up to 100 mappings per read. Any unmapped reads 
were re-aligned to the set of tRNA transcripts with -CCA tails appended, and these were merged 
into the final alignment. For the whole transcriptome libraries, the same extractions were 
performed on brain samples from the same four patients, plus an additional male patient 
(GSE46523). Instead of initial size-fractionation, RNAs were depleted by one round of Ribominus 
(Invitrogen). Additionally, sequences mapping to known rRNA sequences were masked out of the 
dataset, and both adapter-trimmed and untrimmed reads were used. 
 The alignments were also performed using a different alignment program, BWA [102]. 
The results obtained using BWA were nearly identical to those given by Bowtie’s alignments (195 
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modified sites versus Bowtie’s 202). Reads aligning to repeat regions or annotated RNAs other 
than tRNAs were discarded. Nuclear tRNA annotations were taken from the "tRNAs" table in the 
UCSC genome browser (hg19). Annotations for mitochondrial tRNAs were generated by running 
tRNAscan-SE (v1.23) set to organelle mode on the mitochondrial genome (―chrM‖ in hg19). Multi-
mapping reads were partially resolved by taking those alignments whose mismatches aligned to 
SNPs (dbSNP 135) as the true hits, prioritizing them over alignments whose mismatches had no 
apparent explanation. The yeast data, consisting of 20.8 million reads sequenced on an Illumina 
Genome Analyzer I, was obtained from from the NCBI Sequencing Read Archive (GSM775340).  
  
2.2.2. tRNA locus clustering 
 
tRNA loci were taken from the tRNAscan annotation at UCSC and were required to have a 
tRNAscan score of 60.0. The loci were merged into families based on an empirical measure of 
sequence similarity computed from the number of reads mapping across them simultaneously, 
resulting in a clustering of tRNA loci that minimizes the number of cross-mapping reads. Each 
ordered pair of loci (i,j) is assigned a similarity value 
 (   )   
   
   
 
   
 
  where Nij is the number of reads mapping to both loci and the denominator is taken over all loci 
k. Then the symmetric similarity is 
 
 (   )    (   )      * (   )  (   )+ 
 
and the distance is set to be 
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 (   )     (   ). 
 Hierarchical clustering with k=84 clusters yielded the fewest cross-mapping reads with 
the fewest rogue clusters (those whose tRNAs decode to more than one amino acid). The two 
rogue clusters were Gly(SMC)1 containing 1 tRNA
Val
CAC and Cys(NVM)1 containing 6 tRNA
Ala
AGC, 
1 tRNA
Ala
CGC, 3 tRNA
Ala
UGC, 1 tRNA
Ser
AGA, and 1 tRNA
Val
AAC. 
 
2.2.3. Detecting candidate RT misincorporation sites 
 
The read alignment was converted to a pileup format and bases with quality score below 30 were 
discarded. Candidate RT misincorporation sites were taken to be those covered by at least 10 
reads and significantly enriched (FDR<5%) for mismatches by the binomial test, assuming a base 
call error rate of 1%. We tested two null hypotheses. The first, H0
1
, consists of the hypothesis that 
the genotype is homozygous reference. Therefore, the probability of seeing fewer than k out of 
ntot reads matching the reference nucleotide at a given site is  
 
),;(
)nucleotide reference homozygous is genotype site reads, |Pr(    
1
etot
k
i
totref
pniBinom
nkk


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where pe is the base calling error rate. A more conservative null hypothesis, H0
2
 assumes only 
that the genotype is biallelic. It is a composite hypothesis consisting of sub hypotheses for each 
of the 10 possible genotypes. HAMR tests each possible biallelic genotype and takes the 
maximal p-value among all the tested genotypes. The advantage of using H0
2 
is that it will not 
falsely call significant any site that looks like a heterozygous or homozygous SNP. The main 
disadvantage is that it will cause HAMR to miss simple RNA edits as well as modifications that 
produce one- or two-nucleotide patterns in the cDNA. H0
2 
is more appropriate when one wishes to 
avoid false positives due to polymorphisms, but H0
1
 can be used if corroborating DNA evidence or 
other means are available to rule out such false hits. During the scan of the entire small RNA 
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transcriptome, the single nucleotides corresponding to the 5’ and 3’ ends of reads were discarded 
to reduce false positives resulting from elevated base calling error and ligation errors on read-
ends. 
 
2.2.4. tRNA modification identification 
 
RNA modification data was taken from the RNA modification database [129]. Specific locations of 
tRNA modifications were taken from the eukaryotic entries in tRNAdb 2009 and from the curated 
S. cerevisiae data at MODOMICS [38]. The tRNAdb data were given precedence over 
MODOMICS in all cases. Within the tRNAdb data, if multiple modifications were annotated for the 
same site, precedence was given to the organism closest in evolutionary distance from the target 
organism (either human or S. cerevisiae), using divergence time estimates as the means reported 
at timetree.org [75]. For each candidate modification site, an evidence level was assigned based 
on its overlap with the known modification data. The highest confidence overlap is one where a 
candidate modification occurs at a particular site in a particular tRNA for both the prediction and 
in the annotation. The next lowest confidence overlap is one where a known modification occurs 
at that site in any isoacceptor tRNA. Finally, the lowest level of evidence is the presence of a 
known modification in any eukaryotic tRNA at that site. Higher evidence data always takes priority 
over lower evidence data. If multiple possible modifications of the same evidence level are 
annotated at the same site, the modification data is marked as ambiguous. Modified sites were 
plotted on the RFAM consensus tRNA structures using SAVoR [100].  The classifier for 
identifying specific modifications by mismatch pattern is a 3-nearest-neighbor classifier in three 
dimensions, with the features being the sequenced proportions of the three non-reference 
nucleotides, after Laplace smoothing. For training data we only used the highest level of evidence 
(same site, same tRNA) and only modifications supported by at least 3 instances in the RNA-seq 
data were used.  
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2.2.5. Software 
 
The HAMR program takes as input a sequence-read alignment in BAM format (consisting of 
uniquely-mapped reads) and produces a table of genome coordinates and nucleotide frequencies 
at those coordinates. Given an assumed sequencing error-rate, it then performs a statistical 
analysis to select those sites whose mismatch rates are higher than expected by chance. The 
result is a set of sites that consist of both potential SNPs and candidate RNA modifications. 
These sites may optionally be classified as particular modifications based on the models built 
from no-chemical-treatment tRNA data. 
 The web interface allows specification of a remote, indexed BAM file and BED file with 
targeted intervals for querying. The user may specify parameters for the preprocessing steps, 
such as minimum base call quality score, minimum coverage at a site, assumed sequencing error 
rate, and significance level. Additionally, the user may use the software to predict the modification 
type based on mismatch patterns in tRNA data. 
 
2.3. Results 
 
Our method, HAMR, is able to detect the presence of multiple types of modifications present in 
RNA sequenced only once, without chemical treatment. In addition, the signals produced by 
these modifications via modulation of RT activity are present in all types of RNA sequencing 
datasets, which means that HAMR could be invaluable in gleaning more data from previous 
studies or publicly available data. We demonstrate that the method is able to detect modifications 
in two newly generated human RNA datasets as well as a publicly available yeast dataset and 
there is significant overlap in the signal detected. 
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2.3.1. Small RNA-sequencing of tRNA families 
 
tRNAs are the most highly modified cellular RNAs. Since they are highly represented in small 
RNA sequencing libraries as tRNA fragments [22]
 
we developed our approach on this type of 
data, although in principle our method can be applied to any type of RNA-seq dataset. We 
analyzed small RNA-seq data obtained using the dorsolateral prefrontal cortex of four deceased 
human patients who showed no signs of neuropathology. We found that the majority of reads 
(57%) mapped to known microRNAs, 23% to tRNAs, and the rest to other types of known RNAs 
and intergenic regions. 
 Since tRNA loci exist in multiple copies across the human genome, their associated short 
RNA-seq reads will often map to multiple loci.  Simply eliminating the ambiguously mapped reads 
would greatly reduce our data. We reasoned that the exact identity of the tRNA locus was not as 
important as the family producing each read with regards to RNA modification specificity. Given 
that isoacceptor tRNAs (those accepting the same amino acid) tend to have similar sequences 
and isodecoders (those with the same anticodon) even more, we were able to combine similar 
tRNA loci into families and refer to them by their predicted amino acid and anticodon. The 386 
high-scoring tRNA loci annotated by tRNAscan-SE [106] fell into 84 tRNA families that were 
distinct enough to greatly reduce read mapping ambiguity. The post-clustering cross-mapping 
rate (proportion of reads that map to one or more tRNA families) ranged from 9% for shorter 
reads (18 – 20 nucleotides (nt)) down to 2% for longer reads (>31nt). Furthermore, only two 
families included so-called rogue tRNAs, or tRNAs that share sequence identity with their siblings 
but code for a different amino acid.  
 
2.3.2. Detecting modified sites by mismatch rates 
 
In order to detect true post-transcriptional RNA sequence differences, we needed to exclude 
other sources of mismatches such as base calling error and DNA polymorphisms. It is noteworthy 
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that we observed an elevated mismatch rate for tRNA-derived smRNA reads, as would be 
expected when a large number of modified bases are present. In fact, when comparing the 
mismatch rates of reads mapping to tRNAs, microRNAs, and other types of RNAs, we found that 
tRNAs showed an overall elevated level of mismatches, microRNAs showed a spike 
corresponding to the ends of mature miRNAs, and other RNAs showed a gradual increase in 
mismatches towards the 3' ends of reads (Figure 2.1). These data were consistent with high 
numbers of modified bases spread across tRNA reads, with edits/additions at the ends of mature 
microRNAs [21,162], and with simple base calling error, which is expected to increase at the 3' 
ends of longer reads, respectively. The elevated-mismatch sites throughout the length of tRNA-
derived small RNA reads, not just their 3’ ends, suggested that data from smRNA-seq allowed us 
to identify true base pair modifications and not merely sequencing errors. Additionally, the 
distribution of PHRED quality scores at mismatch-containing sites 38.33 (std dev. 2.28) was 
nearly identical to that at non-mismatching sites 38.37 (std dev. 2.28). 
 
Figure 2.1 – Mismatch rates in small RNA reads mapping to three types of RNA 
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 Taking advantage of this observation to identify base modifications transcriptome-wide, 
we developed a model for allowing statistically significant identification of RNA modification sites 
based on nucleotide misincorporation by RT, while ignoring sequencing errors and single 
nucleotide polymorphisms (SNPs) due to genotype.  The model assumes a fixed base calling 
error rate, and makes a set of assumptions about the underlying genotype to model the mismatch 
rate due to chromosomal polymorphism. The simplest null hypothesis, H0
1
, assumes that the site 
is homozygous with the reference allele. Taking this as the null hypothesis results in any non-
reference nucleotide above the base calling error rate being called as a candidate modification.  A 
more conservative null hypothesis, H0
2
, assumes only that the genotype is biallelic. Under this 
assumption, we call candidate modifications where three or more nucleotides are sequenced at a 
rate higher than base call errors. Such patterns will arise at sites of RT misincorporation due to 
modifications and not at biallelic polymorphic sites.  
 We estimated library-wide base calling error to be around 1% based on the observed 
library-wide mismatch rate and on previous reports of error rates in Illumina sequencing [108]. We 
also required coverage of at least 10 reads per nucleotide, including reads with the same start 
and end positions. Under H0
2
, HAMR called 228 candidate modifications out of 5,487 sequenced 
tRNA sites. Of these, 201 (88%) did not overlap with any known SNP in dbSNP release 135 
[134]. Among these 201 sites, 123 (61%) coincided perfectly with a known modification as listed 
in tRNAdb 2009 [142] or MODOMICS [38] and 187 (93%) coincided with sites known to be 
modified on any tRNA (Figure 2.2 and Figure 2.3). 
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Figure 2.2 - Locations of known tRNA modifications predicted to affect RT incorporation 
 
            
Figure 2.3 - Modification sites predicted by HAMR 
 
 In order to test for possible violations of the biallelicity assumption under H0
2
, we 
ascertained the overlap between our called sites and known CNVs. Of the 233 genomic sites 
where we called a modification under H0
2
, 36 (15%) of the candidate sites fall within gain-of-copy 
CNVs listed in the Toronto CNV database [171]. Of the 36 sites in CNVs, 20 fall within rare CNVs 
(only 1 observation) and 16 fall within recurrent CNVs (observed more than once). This suggests 
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that, if the results are false positives due to undiscovered SNPs compounded by copy number 
variation, such instances are only a small fraction of the sites called by HAMR.  
 Since no chemical treatment that allows the identification of a specific post-transcriptional 
modification is used, our approach is limited to detecting modifications that modulate RT 
incorporation during normal sequencing library preparation. We predicted the RT effect of the 
remaining modifications based on their presence along the Watson-Crick edge (on the Watson-
Crick bonds) of the nucleoside (Table 2.1). We found that HAMR exhibits higher sensitivity where 
these types of modifications are predicted to occur (Fig. 3). While inosine (I) is known to produce 
an A>G substitution in cDNA [11] this nucleotide pattern is indistinguishable from an A/G SNP 
and so is discarded under the conservative null hypothesis H0
2
. When we used the less 
conservative null hypothesis, H0
1
, 60% of known inosine edit sites were called (Figure 2.5).   
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Table 2.1 – Selected RNA modifications and their known and predicted effects on RT 
Modification Symbol RT effect W-C edge 
Inosine I Mistranscription [67] Y 
N1-methylinosine m1I  Y 
N1-methyladenosine m1A Can't pair [67] Y 
N2-methyladenosine m2A  N 
N6-
threonylcarbamoyladenosine 
t6A Stop [67] Y 
N6-isopentenyladenosine i6A  Y 
5-methoxycarbonylmethyl-2-
thiouridine 
mcm5s2U  N 
2-methylthio-N6-
isopentenyladenosine 
ms2i6A  Y 
N6-methyl-N6-
threonylcarbamoyladenosine 
m6t6A  Y 
2-methyladenosine m2A  N 
N1-methylguanosine m1G  Y 
N2-methylguanosine m2G Pause [67] Y 
N2,N2-dimethylguanosine m22G  Y 
7-methylguanosine m7G  N 
Wybutosine, 
peroxywybutosine 
yW,o2yW Stop [67] Y 
Queuosine, mannosyl-
queuosine 
Q, manQ  N 
3-methylcytidine m3C  Y 
5-methylcytidine m5C Pairs [67] N 
N4-acetylcytidine ac4C  Y 
5-methyluridine 
(ribothymidine) 
m5U / T Pairs [60] N 
5-carbamoylmethyluridine ncm5U  N 
Dihydrouridine D Can't pair [67], Pairs [60] N 
Pseudouridine Ψ / Y Pairs [67], Pairs [60] N 
2’-O-methyl nucleosides Am, Cm, Gm, Um Pause w/ low dNTP [67] N 
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Figure 2.4 – HAMR’s sensitivity for detecting different types of RNA modification 
 
Figure 2.5 – HAMR’s sensitivity under the loose model H0
1
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2.3.3. Calling modification types by incorporation patterns in RT 
 
We hypothesized that different types of modifications affecting RT incorporation would have 
distinct incorporation patterns due to the differential base-pairing properties of the modified 
ribonucleotides. In order to visualize the incorporation patterns we mapped each potentially 
modified site (excluding known SNPs and using the conservative null hypothesis H0
2
) onto a 
ternary plot with the three dimensions corresponding to observed fractions of the three non-
reference nucleotides. This can be done for each precursor nucleotide separately (A, C, G, and 
U). The ternary plots clearly show clustering by modification type for modified adenosines and 
guanosines (Figure 2.6a,b). Using this approach, we observed thirteen sites for cytidine (m
3
C) 
(Figure 2.7), while predicting two RT-effecting sites for uridine (Figure 2.8). Interestingly, despite 
U>D (dihydrouridine) and U>Y (pseudouridine) not being predicted to affect RT incorporation, we 
were able to detect these sites and they tended to cluster together. We also found that the m
3
C 
sites were sequenced with a very similar nucleotide pattern in all four human brain samples and 
so those observations cluster together. 
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Figure 2.6 – Observed nucleotide frequencies in cDNA for different modification types and in different 
organisms 
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Figure 2.7 – Sequenced nucleotide frequencies at known tRNA m
3
C sites in the human brain 
 
 
 
Figure 2.8 – Sequenced nucleotide frequencies at known modified tRNA uridines in the human brain 
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Amongst modified adenosines, m
1
A shows a bias towards sequencing of T with varying 
amounts of G, and m
1
I shows a very similar pattern. In contrast, t
6
A shows a strong bias towards 
sequencing of C in the cDNA. Under the less conservative H0
1
, 60% of the known inosine sites 
were detected and found to be very strongly associated with a G in the cDNA, as is expected 
(Figure 2.9). At guanosines, both m
2
2G and m
1
G heavily favor sequencing of T with varying 
amounts of C and A, while peroxywybutosine (o2yW) shows more variation. Observations for 
peroxywybutosine were insufficient for us to draw strong conclusions about its RT incorporation 
patterns. 
 
 
Figure 2.9 – Sequenced nucleotide frequencies at guanosines when using the loose model H0
1 
 
 We set out to design a classifier that could take these patterns as input and predict the 
most likely modification at a site using these ternary plots. Given that m
1
A, m
1
I, and ms
2
i
6
A and 
i
6
A and t
6
A co-cluster, we decided to merge these two sets of modifications into the combined 
classes m
1
A|m
1
I|ms
2
i
6
A and i
6
A|t
6
A. Similarly, we merged m
2
G and m
2
2G into a single class, 
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m
2
G|m
2
2G. These two may be especially difficult to resolve because m
2
G is a chemical precursor 
of m
2
2G. Using a 3-nearest-neighbor classifier and leave-one-out cross-validation (LOOCV) we 
were able to differentiate between the two groups of adenosine modifications with 98% accuracy. 
For the guanosine modification types m1G and m
2
G|m
2
2G we were able to achieve 78% 
accuracy. For the 18 observations of significant uridine sites, we were able to distinguish between 
D and Y modifications with 86% accuracy. As there was only one type of cytidine modification 
that was detected, m
3
C, a classifier was not necessary. It is informative, however, that without 
chemical treatment the only cytidine modification we detected was m
3
C. 
 
2.3.4. Expanding the tRNA modification annotation 
 
Given the incomplete nature of the annotation we used, we set out to see if our classifier could 
expand the annotation by predicting modifications across all human tRNAs. We expected that the 
universally conserved modifications, e.g., m
1
A, would appear in all sequenced tRNAs despite 
those sites sometimes being absent from known annotations. Most of the undetected 
modifications were m
2
G sites, and our low sensitivity for m
2
G is likely due to its mild effect on RT 
incorporation [168].  
 In total, we predicted 78 modification sites that were absent from the annotation 
(Supplementary Table 2). In many cases the modifications were absent because the specific 
tRNA was not listed. First, we looked at isoacceptor tRNAs and matched 25 sites to m
1
A9, 
m
1
A58, m
1
G9, m
2
2G26, m
1
G37, m
3
C32, and Y39. For the other 53 sites not previously 
uncovered, we then searched across all tRNAs; this led to an additional 39 matched sites that 
were known to be modified in at least one type of tRNA. The remaining 14 sites were considered 
completely novel. 
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Table 2.2 – All tRNA sites predicted to be modified by HAMR 
tRNA Site Predicted mod type 
Matches 
DB Type 
Glu(UUC)2 C3 m
3
C N/A Novel 
Leu(CAA)1 A26 m
1
A|m
1
I|ms
2
i
6
A N/A Novel 
Met(CAU)1 C20 m
3
C N/A Novel 
Thr(HGU)1 A39 t
6
A N/A Novel 
Thr(UGU)2 A39 t
6
A N/A Novel 
Val(UAC)1 A26 m
1
A|m
1
I|ms
2
i
6
A N/A Novel 
mtAsn(GUU)1 A72 m
1
A|m
1
I|ms
2
i
6
A N/A Novel 
mtAsn(GUU)1 G73 m
1
G N/A Novel 
mtCys(GCA)1 G45 m
1
G N/A Novel 
mtCys(GCA)1 G49 m
1
G N/A Novel 
mtCys(GCA)1 U73 Y N/A Novel 
mtGln(UUG)1 G73 m
1
G N/A Novel 
mtLys(UUU)1 A59 m
1
A|m
1
I|ms
2
i
6
A N/A Novel 
mtPhe(GAA)1 A59 m
1
A|m
1
I|ms
2
i
6
A N/A Novel 
Arg(CCK)1 G39 m
1
G N Known site on other tRNA 
Arg(UCU)3 A38 t
6
A N Known site on other tRNA 
Arg(YCG)1 A38 t
6
A N Known site on other tRNA 
Asp(GUC)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on other tRNA 
Asp(GUC)2 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on other tRNA 
Glu(YUC)1 U33 Y Y Known site on other tRNA 
Lys(UUU)1 A38 t
6
A N Known site on other tRNA 
Met(CAU)1 A38 t
6
A N Known site on other tRNA 
Met(CAU)2 A38 t
6
A N Known site on other tRNA 
Met(CAU)3 A38 t
6
A N Known site on other tRNA 
Pro(HGG)1 G6 No consensus N/A Known site on other tRNA 
Thr(CGU)1 A38 t
6
A N Known site on other tRNA 
Thr(CGU)2 A38 t
6
A N Known site on other tRNA 
Thr(HGU)1 A38 t
6
A N Known site on other tRNA 
Thr(UGU)1 A38 t
6
A N Known site on other tRNA 
Thr(UGU)2 A38 t
6
A N Known site on other tRNA 
Trp(CCA)2 A38 t
6
A N Known site on other tRNA 
Val(CAC)1 U33 Y Y Known site on other tRNA 
Val(UAC)2 G39 m
1
G N Known site on other tRNA 
mtAla(UGC)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on other tRNA 
mtAla(UGC)1 G37 No consensus N/A Known site on other tRNA 
mtArg(UCG)1 A16 m
1
A|m
1
I|ms
2
i
6
A Y Known site on other tRNA 
mtAsn(GUU)1 U1 Y Y Known site on other tRNA 
mtAsn(GUU)1 G26 m
1
G N Known site on other tRNA 
mtCys(GCA)1 G9 m
1
G Y Known site on other tRNA 
mtCys(GCA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on other tRNA 
mtGln(UUG)1 G9 m
1
G Y Known site on other tRNA 
mtGln(UUG)1 U34 Y Y Known site on other tRNA 
mtGln(UUG)1 G37 m
2
G|m
2
2G N Known site on other tRNA 
mtGlu(UUC)1 U33 D N Known site on other tRNA 
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tRNA Site Predicted mod type 
Matches 
DB Type 
mtGlu(UUC)1 U34 D N Known site on other tRNA 
mtLys(UUU)1 U34 D N Known site on other tRNA 
mtMet(CAU)1 C32 m
3
C Y Known site on other tRNA 
mtPhe(GAA)1 U33 Y Y Known site on other tRNA 
mtPro(UGG)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on other tRNA 
mtPro(UGG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on other tRNA 
mtVal(UAC)1 U33 Y Y Known site on other tRNA 
mtVal(UAC)1 U34 D N Known site on other tRNA 
mtVal(UAC)1 U40 D N Known site on other tRNA 
Arg(ACG)1 U39 Y Y Known site on isoacceptor 
Arg(UCG)1 G9 m
2
G|m
2
2G N Known site on isoacceptor 
Arg(UCG)1 G26 m
2
G|m
2
2G Y Known site on isoacceptor 
Arg(UCG)1 G37 m
1
G Y Known site on isoacceptor 
Arg(UCG)1 U39 Y Y Known site on isoacceptor 
Arg(UCG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
Arg(YCG)1 U39 Y Y Known site on isoacceptor 
Ile(UAU)1 G9 m
1
G Y Known site on isoacceptor 
Ile(UAU)1 G26 No consensus N/A Known site on isoacceptor 
Thr(CGU)1 G9 No consensus N/A Known site on isoacceptor 
Thr(CGU)1 G26 m
2
G|m
2
2G Y Known site on isoacceptor 
Thr(CGU)1 C32 m3C Y Known site on isoacceptor 
Thr(CGU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
Thr(CGU)2 G9 No consensus N/A Known site on isoacceptor 
Thr(CGU)2 G26 m
2
G|m
2
2G Y Known site on isoacceptor 
Thr(CGU)2 C32 m
3
C Y Known site on isoacceptor 
Thr(CGU)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
Thr(UGU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
Thr(UGU)2 C32 m
3
C Y Known site on isoacceptor 
Thr(UGU)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
Thr(UGU)3 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
mtGlu(UUC)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
mtHis(GUG)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
mtLys(UUU)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
mtTrp(UCA)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on isoacceptor 
Ala(AGC)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Ala(AGC)1 A37 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ala(AGC)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ala(AGC)3 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Ala(HGC)1 A37 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ala(HGC)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Arg(ACG)1 G9 m
1
G Y Known site on this tRNA 
Arg(ACG)1 G26 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Arg(ACG)1 G37 m
1
G Y Known site on this tRNA 
Arg(ACG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Arg(CCK)1 G9 m
1
G Y Known site on this tRNA 
Arg(UCU)1 G9 m
1
G Y Known site on this tRNA 
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tRNA Site Predicted mod type 
Matches 
DB Type 
Arg(UCU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Arg(UCU)2 G9 m
1
G Y Known site on this tRNA 
Arg(UCU)2 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Arg(UCU)2 C32 m
3
C Y Known site on this tRNA 
Arg(UCU)2 U39 Y Y Known site on this tRNA 
Arg(UCU)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Arg(UCU)3 G9 m
1
G Y Known site on this tRNA 
Arg(UCU)3 C32 m
3
C Y Known site on this tRNA 
Arg(UCU)3 U39 Y Y Known site on this tRNA 
Arg(UCU)3 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Arg(YCG)1 G9 m
1
G Y Known site on this tRNA 
Arg(YCG)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Arg(YCG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Asn(GUU)1 G9 m
1
G Y Known site on this tRNA 
Asp(GUC)1 G6 m
2
G|m
2
2G Y Known site on this tRNA 
Asp(GUC)2 G6 m
2
G|m
2
2G Y Known site on this tRNA 
Cys(NVM)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Gln(CUG)1 G9 m
1
G Y Known site on this tRNA 
Gln(CUG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Gln(UUG)1 G9 m
1
G Y Known site on this tRNA 
Gln(UUG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Glu(UUC)1 G9 m
1
G Y Known site on this tRNA 
Glu(UUC)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Glu(UUC)2 G9 m
1
G Y Known site on this tRNA 
Glu(UUC)2 U34 Y N Known site on this tRNA 
Glu(UUC)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Gly(CCC)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
His(GUG)1 G37 m
1
G Y Known site on this tRNA 
His(GUG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ile(RAU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ile(UAU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Int(CAU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Leu(CAA)2 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Leu(CAA)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Leu(UAA)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Leu(UAA)1 G37 m
1
G Y Known site on this tRNA 
Leu(UAA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Leu(UAG)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Leu(UAG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Leu(UAG)2 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Leu(UAG)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Leu(WAG)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Leu(WAG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Lys(CUU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Lys(UUU)1 A37 t
6
A Y Known site on this tRNA 
Met(CAU)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
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tRNA Site Predicted mod type 
Matches 
DB Type 
Met(CAU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Met(CAU)2 G6 m
2
G|m
2
2G Y Known site on this tRNA 
Met(CAU)2 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Met(CAU)2 U39 Y Y Known site on this tRNA 
Met(CAU)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Met(CAU)3 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Met(CAU)3 U39 Y Y Known site on this tRNA 
Met(CAU)3 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Phe(GAA)1 G37 m
1
G N Known site on this tRNA 
Phe(GAA)1 U39 Y Y Known site on this tRNA 
Phe(GAA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Phe(GAA)2 A14 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Phe(GAA)2 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Phe(GAA)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Pro(HGG)1 U38 Y Y Known site on this tRNA 
Pro(HGG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ser(CGA)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Ser(CGA)1 C32 m
3
C Y Known site on this tRNA 
Ser(CGA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ser(GCU)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Ser(GCU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ser(WGA)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Ser(WGA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Ser(YGA)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Ser(YGA)1 C32 m
3
C Y Known site on this tRNA 
Ser(YGA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Thr(HGU)1 C32 m
3
C Y Known site on this tRNA 
Thr(HGU)1 A37 t
6
A Y Known site on this tRNA 
Thr(HGU)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Trp(CCA)1 G9 m
1
G Y Known site on this tRNA 
Trp(CCA)1 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Trp(CCA)1 G37 m
1
G Y Known site on this tRNA 
Trp(CCA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Trp(CCA)2 G9 m
1
G Y Known site on this tRNA 
Trp(CCA)2 G37 m
1
G Y Known site on this tRNA 
Trp(CCA)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Trp(CCA)3 G9 m
1
G Y Known site on this tRNA 
Trp(CCA)3 G26 m
2
G|m
2
2G Y Known site on this tRNA 
Trp(CCA)3 G37 m
1
G Y Known site on this tRNA 
Trp(CCA)3 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Tyr(GUA)1 U20 D Y Known site on this tRNA 
Tyr(GUA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Val(CAC)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Val(HAC)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Val(UAC)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
Val(UAC)2 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
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tRNA Site Predicted mod type 
Matches 
DB Type 
mtArg(UCG)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtAsn(GUU)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtGly(UCC)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtLeu(UAA)1 G9 m
1
G Y Known site on this tRNA 
mtLeu(UAA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtLeu(UAG)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtLeu(UAG)1 G37 m
1
G Y Known site on this tRNA 
mtLeu(UAG)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtPhe(GAA)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtPhe(GAA)1 A37 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtPro(UGG)1 G37 m
1
G Y Known site on this tRNA 
mtSer(UGA)1 C32 m
3
C Y Known site on this tRNA 
mtSer(UGA)1 A58 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtThr(UGU)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
mtThr(UGU)1 C32 m
3
C Y Known site on this tRNA 
mtTrp(UCA)1 A37 m
1
A|m
1
I|ms
2
i
6
A N Known site on this tRNA 
mtTyr(GUA)1 G9 m
1
G Y Known site on this tRNA 
mtTyr(GUA)1 A37 m
1
A|m
1
I|ms
2
i
6
A N Known site on this tRNA 
mtVal(UAC)1 A9 m
1
A|m
1
I|ms
2
i
6
A Y Known site on this tRNA 
 
2.3.5. Validation in S. cerevisiae small RNA dataset 
 
 In order to validate HAMR and demonstrate its utility in other organisms, we tested the software 
using a previously published yeast small RNA dataset [45].
 
We remapped the reads to the latest 
Saccharomyces cerevisiae genome release (sacCer3, UCSC) and applied the same procedure 
as with the human data to collapse the yeast tRNA loci into families. Of the 3,783 sequenced 
yeast tRNA sites with coverage greater than 10, 67 were called as potentially modified sites. Of 
these, 56 (84%) corresponded exactly to known modifications in tRNAdb or MODOMICS. Six 
more sites corresponded to positions that were not annotated as being modified on their 
particular tRNAs, but were known to be modified in an isoacceptor tRNA. The final five sites were 
known to be modified in other tRNAs. The sensitivity for RT-affecting modification was higher 
than those not predicted to affect RT incorporation (Figure 2.10). Similar to the human data, 
when we used the less conservative null hypothesis H0
1
, we were able to detect 100% of the 
inosine sites, as well as a t
6
A, an m
3
C, and an ac
4
C site (Figure 2.11). 
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Figure 2.10 – HAMR’s sensitivity in an independent S. cerevisiae dataset using the strict model H0
2 
 
Figure 2.11 - HAMR’s sensitivity in an independent S. cerevisiae dataset using the loose model H0
1 
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 The sequenced nucleotide patterns in yeast were similar to those in the human brain 
data.   (Figure 2.6c,d).  The fact that the two datasets were generated using different library 
preparations, sequenced by different versions of Illumina sequencers attests to the robustness of 
the statistical model we have developed. In fact, the classifier trained on human tRNAs was able 
to achieve 90% accuracy for modified adenosines and 65% accuracy for modified guanosines in 
yeast tRNAs. 
 
2.3.6. Validation in human rRNA(-)-seq dataset 
 
In order to ascertain the reproducibility of the tRNA modifications that were not directly present in 
the databases, we generated additional RNA-seq data from whole transcriptome (rRNA-depleted) 
libraries, which include entire tRNAs as opposed to only tRNA fragments. We compared both the 
―seminovel‖ and ―novel‖ tRNA sites in the small RNA libraries to the whole transcriptome libraries 
(Table 2.3). Seminovel here means the site is not annotated as modified on that particular tRNA, 
but is annotated on some other tRNA accepting a different amino acid. Of the 23 seminovel sites 
that were called in more than half of the smRNA libraries, 10 (43%) are also called in at least one 
whole transcriptome library. Two had drastically lower coverage in the whole transcriptome 
libraries. The remaining 13 (mostly ms
2
i
6
A38) sites could not be detected in the whole 
transcriptome libraries, possibly due to a real difference in ms
2
i
6
A modification rates between 
tRNA fragments and whole tRNAs. Of the 6 novel sites detected in more than half of the smRNA 
libraries, 4 were detected in the whole transcriptome libraries. The remaining two had drastically 
lower read coverage in the whole transcriptome libraries. 
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Table 2.3 – Comparison of novel sites in smRNA data to same loci in an rRNA(-) libraries. 
tRNA Site Predicted mod smRNA (/4) rRNA(-) (/5) Low coverage 
mtLys(UUU)1 A59 m
1
A|m
1
I|ms
2
i
6
A 4 5 N 
Val(UAC)1 A26 m
1
A|m
1
I|ms
2
i
6
A 4 2 Y 
mtPhe(GAA)1 A59 m
1
A|m
1
I|ms
2
i
6
A 4 1 Y 
Thr(HGU)1 A39 t
6
A 4 0 Y 
Met(CAU)1 C20 m
3
C 3 5 
 mtAsn(GUU)1 A72 m
1
A|m
1
I|ms
2
i
6
A 3 0 Y 
Glu(UUC)2 C3 m
3
C 2 5 N 
Leu(CAA)1 A26 m
1
A|m
1
I|ms
2
i
6
A 2 0 N 
 
Table 2.4 – Comparison of seminovel sites to rRNA(-) libraries. 
tRNA Site Known mod smRNA (/4) rRNA(-) (/5) 
Low 
coverage 
Asp(GUC)1 A9 m
1
A 4 5 N 
Asp(GUC)2 A9 m
1
A 4 5 N 
Pro(HGG)1 G6 m
2
G 4 5 N 
mtAla(UGC)1 A9 m
1
A 4 5 N 
mtAla(UGC)1 G37 m
1
G|o2yW 4 5 N 
mtGln(UUG)1 G37 m
1
G|o2yW 4 5 N 
mtPro(UGG)1 A9 m
1
A 4 5 N 
mtCys(GCA)1 G9 m
1
G|m
2
G|xG 4 4 N 
mtGlu(UUC)1 U34 xU 4 2 N 
Arg(YCG)1 A38 ms
2
i
6
A 4 0 N 
Lys(UUU)1 A38 ms
2
i
6
A 4 0 Y 
Met(CAU)3 A38 ms
2
i
6
A 4 0 N 
Thr(HGU)1 A38 ms
2
i
6
A 4 0 N 
mtPhe(GAA)1 U33 Y 4 0 N 
mtVal(UAC)1 U34 xU 4 0 N 
mtLys(UUU)1 U34 xU 3 3 N 
Arg(CCK)1 G39 Gm 3 0 N 
Arg(UCU)3 A38 ms
2
i
6
A 3 0 Y 
Met(CAU)1 A38 ms
2
i
6
A 3 0 N 
Met(CAU)2 A38 ms
2
i
6
A 3 0 N 
Thr(CGU)1 A38 ms
2
i
6
A 3 0 N 
Thr(UGU)2 A38 ms
2
i
6
A 3 0 N 
mtAsn(GUU)1 U1 Y 3 0 N 
Glu(YUC)1 U33 Y 2 0 N 
Thr(CGU)2 A38 ms
2
i
6
A 2 0 N 
Thr(UGU)1 A38 ms
2
i
6
A 2 0 N 
Val(UAC)2 G39 Gm 2 0 N 
mtCys(GCA)1 A58 m
1
A 2 0 N 
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2.3.7. Detecting modifications in other RNAs 
 
Scanning the entire human small RNA transcriptome and excluding tRNAs revealed 73 sites with 
mismatch patterns potentially corresponding to RNA modifications (Table 2.5). Nearly half (36) of 
these sites fell within known pre-microRNAs. Since the microRNA sites nearly always fell within 2 
nucleotides of the 3’ ends of mature microRNAs as annotated by mirBase [93], they most likely 
correspond to untemplated nucleotide additions, a phenomenon that has previously been 
observed in small RNA-seq datasets [31]. 
Table 2.5 – Candidate sites of modification across the entire small RNAome 
RNA type No. sites 
tRNA 166 
miRNA 36 
mt-tRNA 13 
intergenic 11 
mRNA_intron 5 
rRNA 5 
transposon 4 
ncRNA_exon 3 
Antisense mRNA exon 2 
Antisense transposon 2 
snRNA 2 
Antisense mRNA intron 1 
Antisense ncRNA exon 1 
scRNA 1 
 
2.3.8. Software 
  
Users may submit a link to a remote indexed BAM (read alignment) file to the online version of 
HAMR. HAMR detects candidate modification sites either transcriptome-wide or at selected loci 
specified by transcript ID or genomic coordinates. Users may also opt to filter out known dbSNP 
sites for human data and select various options affecting the stringency of the analysis, including 
p-value or FDR thresholds, minimum coverage, and which null hypothesis to use. The web 
version of HAMR is available at http://wanglab.pcbi.upenn.edu/hamr. 
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2.4. Discussion 
 
Here we present HAMR, a high-throughput method to map RNA modifications within all classes 
of RNAs by identifying misincorporation of nucleotides by reverse transcriptase during production 
of cDNA products. While traditional methods use chemical treatment of the RNAs prior to RT, 
many modifications are still detectable even without treatment due to their effect on RT 
incorporation. This is advantageous because it allows for retrospective assays of potential RNA 
modifications in existing RNA-seq datasets, and also because it allows for the detection of RNA 
modifications with only one sequencing run. However, it is worth noting that the use of different 
chemical treatments in addition to different types of RT enzymes should expand the range of 
modifications that are detectable by HAMR. Since many modifications also cause complete halts 
in RT, a future research direction is to develop a method that allows the utilization fragment 
endpoint locations for modification mapping. 
 We have also found that the number of allowed mismatches in read alignment places a 
limit on the detection of nearby modifications. Improvement of methods, like the one presented 
here, will thus necessitate development of an alignment method that allows mismatches at 
arbitrary sites. This would be similar to the mapping methods used for bisulfite sequencing data 
[163], which are designed to map reads accurately in the face of cytosine deamination. 
 
2.5. Acknowledgements 
 
Brain samples were obtained from the Center for Neurodegenerative Disease Research at the 
University of Pennsylvania. RNA-seq experiments were carried out with help from Vivianna M. 
Van Deerlin, Virginia Lee, John Q. Trojanowski, Alice Chen-Plotkin, Gerard D. Schellenberg, and 
52 
 
Steven E. Arnold, and their lab members. We thank Mingyao Li, Zissimos Mourelatos, and the 
members of the Wang and Gregory labs for their comments. 
  
53 
 
3. Classification of RNAs by Analysis of 
Length (CoRAL) 
 
Appeared in: Leung YY*, Ryvkin P*, Ungar LH, Gregory BD, Wang L-S. CoRAL: predicting non-
coding RNAs from small RNA-sequencing data. Nucleic Acids Res. 2013. (*Joint first authors) 
 
3.1. Introduction 
One of the most significant biological discoveries of the last decade includes the discovery of new 
types of RNAs and their specific functions in eukaryotic cells [48,153]. For instance, non-coding 
RNAs (ncRNAs) are transcripts that are not translated into proteins but serve other important 
biological functions. ncRNAs have highly diverse functions including protein translation (transfer 
RNAs (tRNAs) and ribosomal RNAs (rRNAs)), regulation of gene expression (microRNAs 
(miRNAs) and long intergenic non-coding RNAs (lincRNAs)) [71,87], pre-mRNA splicing (small 
nuclear RNAs (snRNAs)) [16], RNA modification (small nucleolar RNAs (snoRNAs)) [111], and 
the list is still expanding. Advances in high-throughput sequencing technologies have led to the 
unexpected discovery that up to 93% of the human genome is transcribed in some tissues [25]. 
Thus, it is not surprising that the non-coding RNA database [19] includes 135 different ncRNA 
classes. Unfortunately, the classification of most RNAs in this database is more representative of 
the historical process by which the ncRNAs were discovered such as sedimentation coefficient 
(e.g. 4.5S RNA) or cellular location (e.g. snoRNA), than of their true cellular function. This gap 
highlights the fact that most transcribed regions are still of unknown molecular function and 
biological significance.  
Given that little is known about most ncRNAs, a potential approach is to gather an enormous 
amount of experimental data efficiently and systematically using RNA-seq, and analyze these 
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data using sophisticated computational approaches. Unlike microarrays, RNA-seq does not rely 
on target probe hybridization, and thus one does not need to know in advance which regions are 
being transcribed. These properties make RNA-seq a promising tool to study ncRNA biology. 
Additionally, RNA-seq is highly versatile in that it can be modified to study specific properties, e.g. 
small RNA sequencing (smRNA-seq) [95] where gel-based size selection is used to enrich for 
RNAs with particular sequence lengths.  
While traditional methods predict RNA function using primary sequence or alignment 
information, new approaches using RNA-seq data have been proposed. For example, the 
miRDeep2 algorithm [58] searches for genomic regions that fold into hairpin structures and are 
enriched for sequenced reads next to the hairpin loop region (the expected location of mature 
miRNAs) to identify potential miRNA loci. Additionally, Langenberger et al. [96] pioneered the use 
of smRNA-seq features such as abundance and block length distribution to classify ncRNAs. 
Their method DARIO [53] uses random forest (RF) classifiers to differentiate between tRNA, 
miRNA, and snoRNA loci with reasonable performance. However, features generated from 
DARIO are not normalized by transcript-wide abundance; as a result, the most informative feature 
for miRNA identification is their overall abundance. This does not generalize well to other ncRNAs 
and is simply a result of the fact that miRNAs are highly abundant in human smRNA-seq 
datasets. 
Erhard and Zimmer [50] used similarities between RNA transcripts to classify ncRNAs. Their 
similarity measure was created based on the relative positions and lengths obtained from 
sequencing experiments. However, relative positions of reads require good knowledge on the 
start- and end-points of transcripts within a genome sequence, which is a challenge for newly 
discovered classes of ncRNA. Evaluation of their method on two classes of RNA (miRNAs and 
tRNAs) yielded performance with recall values of 98% and precision of 60% for miRNAs and 
~80% for tRNAs, which leaves room for improvement.  
To address the limitations of these previous RNA function classifiers, we have developed a 
framework for classifying RNA transcripts by functional categories using smRNA-seq data (Fig. 
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1), which can then be applied to identify unannotated RNAs with similar functions in other 
organisms in the future. To do this, we first designed algorithms to generate several types of 
features from smRNA-seq data based on read length distribution, strand specificity, and the 
secondary structure of the transcript for transcribed genomic regions. We then applied a multi-
class classification algorithm with feature selection and cross validation schemes included to train 
classifiers among a collection of known RNA functional classes including lincRNAs, miRNAs, 
scRNAs, C/D box snoRNAs, snRNAs, and transposon-derived RNAs. For each RNA class, we 
identified the most informative features that might be associated with the molecular mechanisms 
and metabolic processes of the functional classes. Trained models, informative features, and 
annotation results have been validated using: 1) external datasets, 2) SAVoR [100], a 
visualisation tool for RNA structures [101], and 3) curation of the primary literature. 
 
3.2. Methods 
3.2.1. Processing of small RNA-seq data  
The smRNA-seq data used for our analysis came from four sources: human brain data generated 
as part of this study (GSE43335), a previously published dataset from human skin (GSE31037) 
[86], and published datasets from human liver (SRR040571) and muscle (SRR040572) [52]. The 
human brain data was obtained by sequencing small RNAs (smRNAs) extracted from the 
dorsolateral prefrontal cortex of four deceased human patients with no apparent pathology. All 
reads were trimmed to remove the Illumina 3’ adapter sequence using cutadapt [110], and only 
those reads containing the adapter were taken as true smRNA reads. Reads were mapped to the 
reference genome GRCh37/hg19 using Bowtie [97] and those mapping to multiple loci were 
discarded. In order to merge reads into transcribed loci, we used the RSEQTools’ [72] 
bgrSegmenter tool. (Table 3.1) 
  
56 
 
 
Table 3.1 – Number of reads and loci at each stage of smRNA-seq processing 
 Raw 
reads 
(millions) 
3’ adapter 
trimmed 
reads 
(millions) 
Uniquely 
mapped 
reads 
(millions) 
Small RNA 
loci, > 1 read 
Small RNA 
loci, > 15 reads 
Brain 104.1 51.9 (50%) 15.4 (30%) 6,246 4,525 (72%) 
Skin 307.0 188.4 (61%) 85.4 (28%) 11,423 8,638 (76%) 
Liver 3.37 1.48 (44%) 1.15 (78%) 269 216 (80%) 
Muscle 3.79 3.42 (90%) 0.368 (11%) 218 178 (82%) 
 
3.2.2. Labelling training data  
Functional categories were assigned to loci by overlapping their coordinates with RNA 
annotations from the UCSC Genome Browser [59]. While there are many different types of 
ncRNA described, we focused on a subset of functional classes where sufficient numbers of 
confirmed loci were available to train predictive models.  
For quality control purposes, loci covered by fewer than 15 reads were discarded. This value 
was chosen as a compromise between selecting high quality sufficiently transcribed regions and 
identifying significant levels of loci for each class (Figure 3.1). Based on these criteria the 
following six RNA classes were selected: lincRNAs, miRNAs, scRNAs, C/D box snoRNAs, 
snRNAs and transposon-derived RNAs (Figure 3.2 and Figure 3.3). We excluded rRNAs and 
tRNAs because they are easily identifiable by sequence homology alone. 
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Figure 3.1 – The effect of read count thresholds on the ability to detect smRNA loci 
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Figure 3.2 – Summary of RNA classes in the brain smRNA-seq 
 
 
 
Figure 3.3 – Summary of RNA classes in the skin smRNA-seq 
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3.2.3. Feature generation 
We noted that features used for classification purposes should be flexible, comprehensive, 
efficient, and scalable. Therefore, we developed features that would be most likely to reflect the 
underlying biological properties of small ncRNAs. For example, microRNAs are consistently 
processed into their mature form of 22 nucleotide (nt) fragments as a consequence of Dicer’s 
activity on the stem-loop structure of pre-microRNAs [10]. It is reasonable to assume, then, that 
the lengths of smRNAs are consistent with some aspects of their biogenesis, which should also 
be consistent within classes sharing the same molecular function. Thus, for a transcribed locus i 
that starts at genomic position a and ends at position b, we define the length features as: 



b
ak
Lk
iL
(i)
N
s
Length
 
for read lengths 3014  L  , where NLk is the number of reads of length L mapping to base k 
and Length (i) is the length of locus i. The values of these 17 features are then transformed into 
log-odds-ratios via the following normalization procedure: 
piL =
1+ siL
siL
14£L£30
å
, xiL = log
piL
1/17
æ
è
ç
ö
ø
÷ 
In addition to the read lengths, we introduced a feature based on the abundance of antisense 
transcription. The numerical value of this feature reflects the number of reads mapped to the 
antisense strand of the transcribed locus. This feature is generated based on the assumption that 
the presence of antisense transcription at a locus is relevant to the biogenesis of smRNAs from 
this region. Another important feature that is likely to be specific to smRNA biogenesis is the 
specificity of cleavage positions. We encode this as two features: 5’ and 3’ positional entropy. The 
entropy is computed based on the distributions of the 5’ and 3’ end positions of all smRNA reads 
mapped to a given locus, respectively. This entropy feature is designed to capture the specificity 
(or degeneracy) of RNA cleaving-enzymes specific to the production of different types of 
smRNAs. For example, the processing of mature microRNAs from pre-microRNAs tends to 
produce fragments with a more stable 5’ cleavage position (low entropy) and more variable 3’ end 
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(higher entropy). We also generate features corresponding to the base composition of the reads, 
weighted by their expression: these are the four nucleotide frequencies transformed into a log-
odds ratio relative to equal base frequencies. Additionally, we compute the predicted minimum 
free energy of the genomic region surrounding the transcribed locus (40 bp on either side) using 
RNAfold with the default parameters [78]. 
 
3.2.4. Feature selection and classification framework  
In order to identify features that are most representative of the six ncRNA classes, we used the R 
package varSelRF (version 0.7-3) [41], which finds a small, optimal set of non-redundant features 
for each class. When computing the feature importance we used varSelRF with parameters 
(mtryFactor=4, vars.drop.fac = 0.35, ntree = 1e3). For the number of variables mtryFactor setting 
we tried various values and saw no difference in performance, so we used a value corresponding 
to the square root of the number of features as recommended in the literature [144]. Similarly, the 
number of trees did not greatly affect accuracy but had a large impact on running time. The 
selected variable drop factor yielded classifiers with the highest training accuracy. Random forest 
was used as a classifier to distinguish between multiple RNA classes. The feature selection 
portion uses both backwards variable elimination and selection based on the variable importance 
index outputted by the RF model. When training the models, 100 RF models comprised of 1000 
trees were built to determine the stability of results.  
 
3.2.5. Evaluation of performance 
Typically the performance of a binary-class classifier is evaluated by comparing values from the 
confusion matrix, including rates of true positives (TP), true negatives (TN), false positives (FP), 
and false negatives (FN). Other commonly used measures for binary classification are accuracy, 
recall/sensitivity, and positive predictive value. Measures for multi-class classification are 
generalized from measures used in binary classification. ACCk is the overall accuracy, which is 
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the proportion of predictions that are correct: ACCk = (TPk+TNk)/(TPk+TNk+FPk+FNk). For every 
class Ck, the class-specific evaluation measures are defined by recall (RECk) and positive 
predictive value (PPVk), derived from counts of Ck from the confusion matrix. RECk is defined as 
the proportion of positive labelled samples that are predicted as positive: RECk = TPk/(TPk+FNk), 
whereas PPVk is defined as the proportion of positive samples that are correctly identified: PPVk 
= TPk/(TPk+FPk).  
 
3.3. Results 
3.3.1. Visualization of the length features  
We hypothesized that the lengths of some small ncRNAs are specific to particular classes of 
precursor ncRNAs. Therefore, we tested the distribution of the read length feature for three of the 
ncRNA classes in the human brain and skin datasets. miRNAs demonstrated a strong peak at 22 
nt in length (Figure 3.4, Figure 3.3, and Figure 3.10), which is consistent with what is known 
about the length of mature miRNAs in animals. Products coming from C/D box snoRNAs tend to 
be depleted of shorter RNAs and enriched for longer RNAs (Figure 3.6, Figure 3.7, and Figure 
3.11). Transposon-derived smRNAs appear to show slightly different distributions depending on 
the tissue type. For example, they show a weak broad peak around 19 – 23 nt in the brain data 
and a flatter, weaker bias towards 16 – 22 nt in the skin data (Figure 3.8, Figure 3.9, and Figure 
3.12). 
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Figure 3.4 – Read length spectrum for brain miRNAs 
 
 
Figure 3.5 – Read length spectrum for skin miRNAs 
   
 
Figure 3.6 – Read length spectrum for brain C/D box snoRNAs 
 
Figure 3.7 – Read length spectrum for skin C/D box snoRNAs 
 
63 
 
 
Figure 3.8 – Read length spectrum for brain transposon-derived smRNAs 
 
Figure 3.9 – Read length spectrum for skin transposon-derived smRNAs 
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Figure 3.10 – SAVoR plot for a brain microRNA 
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Figure 3.11 – SAVoR plot for a brain C/D box snoRNA 
 
 
Figure 3.12 – SAVoR plot for a brain transposon-derived smRNA locus 
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In addition, we examined the correlations among the features in the brain dataset (Figure 3.13). 
Unsurprisingly, features corresponding to adjacent lengths correlate very strongly. Interestingly, 
there appear to be four clusters of lengths: 14 – 18 nt, 19 – 20 nt, 21 – 23 nt, and 24 – 30 nt. 
These results suggest that specific classes of smRNAs tend to have coherent lengths. We also 
found that positional entropy at both ends of human brain small RNAs strongly correlate. This 
suggests that small RNAs with high 5’ cleavage specificity tend to also have high 3’ cleavage 
specificity. 
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Figure 3.13 – Correlation heatmap of all the features in the brain data 
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3.3.2. Discriminative power of features  
Due to the varying number of loci within each ncRNA class, it can be challenging to visualize all 
loci in a dataset. In order to determine how well the length features were able to separate the loci, 
we built RF trees by classifying one ncRNA class versus all other classes. We then applied 
multidimensional scaling (MDS) to the proximity matrix obtained from the RF trees. miRNA, C/D 
box snoRNAs, and transposon-derived RNAs were the most visually distinguishable classes of 
smRNAs using our features (Figure 3.14 and Figure 3.15), and this pattern was found to be 
consistent between the two (brain and skin) datasets. 
 
 
 
Figure 3.14 – Multidimensional-scaling projection of the features in the brain data 
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Figure 3.15 - Multidimensional-scaling projection of the features in the skin data 
 
 
3.3.3. Comparison with existing classification approaches – DARIO and miRDeep 
We compared our method with a published method (DARIO), which was designed for classifying 
smRNAs by their precursor ncRNA loci. Since DARIO only uses three classes of ncRNAs 
(miRNAs, C/D box snoRNAs, and tRNAs) for building its classification model, we ran CoRAL 
while limiting the data to those three classes only (Table 3.2). 
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Table 3.2 – Comparison of a 3-class CoRAL model to DARIO 
 
DARIO CoRAL 
miRNA 
REC (%) 90 94 
PPV (%) 92 95 
C/D box snoRNA 
REC (%) N/A 88 
PPV (%) N/A 91 
tRNA 
REC (%) 84 90 
PPV (%) 81 87 
Overall accuracy (%) 87 91 
 
CoRAL gives the best results for all three classes, with an improvement of ~ 3 – 4% for 
miRNAs and tRNAs. DARIO reported none of the loci as being annotated as snoRNAs and so 
that class was unable to be compared, but demonstrates that CoRAL is able to identify these 
RNAs that cannot be distinguished by DARIO. When restricting the comparison to miRNAs and 
tRNAs, CoRAL’s predictive performance is 91%, which is a 4% improvement over the same 
analysis performed by DARIO.  
Additionally, we compared our results to those produced by miRDeep2 on the brain data (ran 
with default parameters). miRDeep2 had a recall of 81% and PPV of 98%, whereas CoRAL had a 
recall of 88% and PPV of 91% for miRNAs, while also predicting 5 other RNA classes. Thus, 
CoRAL has increased functional classification capabilities as well as improved overall 
performance compared the to currently available classifier options. 
 
3.3.4. Building a classification model using 6 classes of ncRNAs 
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There are currently more than 135 classes of ncRNAs in the NONCODE database. Here, we 
focused on a subset of functional classes where sufficient numbers of confirmed loci were 
available for us to build our predictive models. A total of six classes were included: lincRNAs, 
miRNAs, scRNAs, C/D box snoRNAs, snRNAs, and transposon-derived smRNAs. Performance 
measures were averaged over 1000 different seeds of RF classifiers (Table 3.3).    
 
Table 3.3 – Cross-tissue comparison of a 6-class CoRAL classifier 
 
Brain Skin 
CoRAL Baseline CoRAL Baseline 
lincRNA 
Count 13 34 
Recall (%) 16 0 1 1 
PPV    (%) 62 0 38 2 
miRNA 
Count 397 465 
Recall (%) 91 78 89 71 
PPV    (%) 88 43 86 42 
scRNA 
Count 93 41 
Recall (%) 78 1 29 0 
PPV    (%) 81 7 49 0 
C/D box 
snoRNA 
Count 209 176 
Recall (%) 94 14 88 5 
PPV    (%) 79 22 81 15 
snRNA 
Count 87 113 
Recall (%) 28 1 57 1 
PPV    (%) 67 7 67 9 
transposon 
Count 187 361 
Recall (%) 77 5 80 24 
PPV    (%) 74 15 77 28 
Overall 
Count 986 1190 
Accuracy (%) 81 33 79 33 
 
For both datasets, the overall accuracy is approximately 80%, which is a significant 
improvement over the baseline of 33%. The best performing classes are miRNA, C/D box 
snoRNA, and transposon-derived RNAs. The performance of these three classes is also 
consistent between the two tissue types. In contrast, the lincRNA, scRNA, and snRNA classes 
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performed more poorly. The lower performance of these classes can possibly be attributed to 
their smaller representation among loci, since there were fewer smRNA loci present from these 
regions for both tissue types. Another potential reason for the lower performance is that these 
classes are less cohesive than the other classes. lincRNAs generally do not share any structural 
properties and are known to have diverse functional roles [24]. scRNAs are in fact an umbrella 
group for two distinct types of RNAs: human Y (HY) RNAs and the BC200 small cytoplasmic RNA  
[152], which have different secondary structures and likely different functions in the cell. Finally, 
the snRNA class is a highly incoherent grouping due to the structural diversity among its 
members. For example, while the U1 and U2 RNAs are both small, localized to the nucleus, and 
involved in pre-mRNA splicing, they perform very different functions and have very different 
secondary structures [16]. Therefore, it is reasonable to expect more diversity in the properties of 
smRNAs being produced by cleavage of snRNAs as opposed to the three better performing RNA 
classes.  
 
3.3.5. Features that can discriminate between classes of small RNAs 
While we were interested in comparing the reproducibility of the smRNA features for various 
ncRNA classes, an important biological question to ask is which features are specific to which 
ncRNA classes. To determine this, we counted the number of times a feature is selected out of 
the 1000 RF models (Figure 3.16). In order to provide potentially biologically informative insights, 
we also marked features as being lower- or higher-valued in one class than in the others. We 
found that smRNAs from C/D box snoRNAs often have a higher positional entropy at their 5’ end 
and are very short (< 16 nt) or long (> 25nt). Interestingly, the length bias for these smRNAs is 
more marked in the brain data than in the skin data, but the entropy bias is consistent between 
tissues. snRNAs do not have many discriminative features in the skin dataset but in the brain they 
seem to preferentially produce shorter RNAs. Transposon-derived RNAs show very low positional 
entropy – suggesting that their cleavage positions tend to be very consistent. They also seem to 
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be depleted of miRNA-length products (22 – 24 nt), while being enriched for shorter products (< 
19nt) and having high minimum free energy (MFE) values for their secondary structure. 
 
Figure 3.16 - Feature importance map of the 6-class classifier for each tissue 
 
 We found the class-specific features were largely consistent across the two tissues, but vary 
widely for the ncRNA classes under study. For instance, lincRNAs show a propensity to produce 
shorter RNAs (14 – 17 nt), with slightly longer RNAs being produced in the skin data. Additionally, 
miRNAs were broadly distinguished by the production of fragments between 20 and 23 nt long, 
and this was very consistent between the tissue types. They also display a strong bias for low 5’ 
positional entropy and high 3’ entropy. This mirrors what is already known about lower variability 
of miRNA cleavage at the 5’ end and higher variability at the 3’ end [46]. 
Small cytoplasmic RNA (scRNA)-derived smRNAs demonstrated a broad peak of 
discrimination at 27 nt for both tissue types, with skin RNAs showing longer lengths. It has 
previously been shown that Y RNA (a type of scRNA) fragments do produce miRNA-like smRNAs 
but their potential function is still unclear [158]. scRNA-derived RNAs are moderately consistent 
between the two tissue types, but consistently show a preference for longer products with high 
MFE values. 
74 
 
Similar to scRNAs, C/D box snoRNAs were found to produce longer fragments. In both 
tissues, the positional entropy at both ends of the resulting smRNAs tended to be high, indicating 
a great degree of variability in cleavage positions. The pattern for snRNAs was less clear 
because their processing was highly inconsistent between the tissue types, with the exception of 
the production of 14 nt fragments, which was seen in both the brain and skin datasets. This may 
be due to the heterogeneity in the properties (especially structural) of RNAs that are collectively 
referred to as snRNAs. In contrast, we found that the features distinguishing transposable 
element-derived smRNAs were almost entirely consistent between the two tissues. With the most 
discriminative features being high cleavage specificity, high MFE, smaller products, and the 
absence of miRNA-sized products. Thus, determining the mechanism of transposon-derived 
smRNA processing and their functions will likely be an interesting future research direction. 
In order to determine whether a subset of features was the most useful for overall 
classification we selected the first five dimensions from the MDS analysis. This resulted in a drop 
in overall accuracy of 8% (data not shown). This suggests that while a small number of features 
capture most of the differences between the classes, many other features are still highly 
informative. More importantly, results obtained from the original features are more conducive to 
interpretation than a model that is only generated based on a projection of the original features. 
 
3.3.6. Validation of the classification models between datasets 
In order to evaluate the robustness of our classification models, we performed validation using 
independent datasets. In order to do this, we trained RF models on the brain data and applied 
them to the skin data and vice versa. Overall, the models were found to work fairly well, showing 
an accuracy of approximately 80% in both cases (Table 3.3). This suggests that patterns of 
smRNAs produced from ncRNAs are generally consistent and mostly non-tissue specific. 
However, we found that the degree of consistency varies among the classes of smRNAs. 
miRNAs, C/D box snoRNAs, and transposon-derived RNAs show the most consistent results 
both within and between tissue types. However, the lincRNA and snRNA classes display very 
75 
 
tissue-specific patterns of smRNA processing (Table 3.3). This is expected for lincRNAs given 
their tissue-specific patterns of expression. Besides tissue specificity, one other potential reason 
why certain classes perform much better across tissue types may be the number of loci present 
within the tissues being used for analysis. Since we are using a fixed minimum of 20 reads 
mapping to each locus, differences in overall expression between the tissue types will result in a 
different number of loci in each class (Figure 3.17, Figure 3.18, Figure 3.19, Figure 3.20, 
Figure 3.21, and Figure 3.22). Therefore, while the cross-tissue classifier performs well overall, it 
is limited by not only the number of loci in each class but also the consistency in these numbers 
across the tissue types being studied.  
 
Figure 3.17 – lincRNA-derived smRNA locus overlap between brain and skin 
 
Figure 3.18 - miRNA locus overlap between brain and skin 
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Figure 3.19 - scRNA-derived smRNA locus overlap between brain and skin 
 
Figure 3.20 – C/D box snoRNA-derived smRNA locus overlap between brain and skin 
 
 
Figure 3.21 - snRNA-derived smRNA locus overlap between brain and skin 
 
 
Figure 3.22 - Transposon-derived smRNA locus overlap between brain and skin 
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In order to further vaildate the robustness of the classifier when applied to different datasets, 
we tested additional publically-available smRNA-seq datasets for human liver and muscle (Table 
3.4). We restricted the classes to those represented by at least 10 loci in all four datasets 
(miRNA, C/D box snoRNA, and tRNA). For each pair of datasets we trained the model on one 
and tested on the other. Overall the accuracies (65-93%) suggest that the model can classify 
across tissue types fairly well, conditional on the training dataset having high enough sequencing 
depth to fully characterize the lower-abundance small RNAs. For example, the liver dataset has 
far fewer reads than the others and thus performed poorest (<70%) when used as the training 
dataset. Despite this, the model was able to classify liver smRNAs fairly well (77-93%) when 
trained on the other tissue types. Overall, our results suggest that CoRAL is a comprehensive 
and robust method for classifying RNAs using smRNA-seq datasets. 
 
Table 3.4 – Four-way independent cross-validation of the 3-class classifier 
 Test    
Train Brain Skin Liver Muscle 
Brain 91% 87% 93% 91% 
Skin 81% 89% 81% 90% 
Liver 71% 67% 93% 92% 
Muscle 63% 67% 93% 100% 
 
3.4. Conclusions  
Patterns of cleavage in human ncRNAs appear to be non-random and reflect specificity in the 
processes that produce smRNAs from the corresponding precursors. This is despite the fact that 
the classes of ncRNAs studied here are defined based on differing criteria (sequence homology, 
secondary structure homology, biological function, cellular localization, and transcript length). 
While it is unknown whether these fragments or the cleavage of the precursors have some 
biological function, the non-random nature of the cleavage events hints at some role. 
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We also found that the classification features that distinguished each class of ncRNA are 
generally consistent across tissue types in humans, suggesting there are as-yet unknown 
biological pathways regulating their biogenesis. We also demonstrated that some types of 
ncRNAs show more tissue specific properties (lincRNAs, scRNAs, and snRNAs). However, the 
other three RNA classes (miRNAs, C/D box snoRNAs, and transposon-derived RNAs) are highly 
reproducible and consistent across two of the tissue types tested in our study.  
As compared to previous work like DARIO, one of the significant contributions of CoRAL is the 
development of biologically interpretable features such as fragment length, cleavage specificity, 
and antisense transcription. These features are able to capture the essence of ncRNAs, i.e., how 
they are processed into smaller fragments. It seems likely that the features revealed by CoRAL 
can serve as a basis for further exploration and validation.  
The ability of CoRAL to consistently annotate loci between tissue types suggests that it may 
be useful in annotating ncRNAs in other organisms and even more tissue types using only 
smRNA sequencing data. Thus, it will be a powerful tool for the annotation of future non-coding 
transcriptomes in this era of genomic progress, which complements other currently available 
comparative genomics methodologies.  It is worth noting that our approach may even outperform 
homology-based methods, given the lower homology due to compensatory evolution in many 
classes of RNAs [113]. 
 
3.4.1. Software Availability 
The CoRAL source code required genome annotation files, and prediction results are available at: 
http://wanglab.pcbi.upenn.edu/coral . 
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4. Characterizing the non-coding 
transcriptome of Alzheimer’s Disease 
 
4.1. Introduction 
Studies of the transcriptome in Alzheimer’s disease are not new [15,17,33,104,116,155]. 
However, all of these studies tend to focus on the protein-coding portion of the transcriptome 
while ignoring the non-coding portion. While there is a preponderance of functional data for 
proteins (often of a non-directional nature such as simple binding or association), an advantage of 
studying non-coding RNAs is that there are also many known directional relationships amongst 
them. For example, snRNAs direct splicing of pre-mRNAs; another example is that of ribosomal 
RNAs, differential expression of which might indicate a global downregulation of translation in the 
face of environmental stress. Another example is that of tRNAs as, again, markers of cellular 
stress – in particular, small RNAs deriving from their cleavage. Here we present a study of the 
non-coding transcriptome (both long and short) transcripts in the dorsolateral prefrontal cortex of 
the AD-affected brain. 
4.2. Methods 
4.2.1. RNA-sequencing 
The small RNA and rRNA(-) sequencing were performed as described in section 2.2.1. 
4.2.2. Calling small RNA loci and building smRNA locus families 
By taking uniquely-mapping reads only, we can lose up to 60% of the reads in a small RNA 
library. We can mitigate this issue by keeping some cross-mapping reads and losing the ability to 
distinguish between different loci that are copies of the same or very similar gene (this is 
acceptable as they will never be resolvable at a given read-length.) In order to accomplish this, 
the method for clustering tRNAs by empirical cross-mapping rates in Chapter 2 was generalized 
and adapted to all small RNA loci in a transcriptome. Here the clustering quality criterion was 
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defined so as to minimize inclusion of multiple RNA classes into one cluster, and the value of K (# 
clusters) was chosen to minimize this value. Clusters were heavily penalized if they contained loci 
coming from a priori pairs defined as incompatible (Table 4.1). 
Table 4.1 – RNA classes defined as incompatible when clustering loci. 
RNA class Incompatible classes 
miRNA tRNA, mt-tRNA, snoRNA, snRNA, rRNA 
tRNA miRNA, snoRNA, snRNA, rRNA 
mt-tRNA miRNA, snoRNA, snRNA, rRNA 
snoRNA miRNA, tRNA, mt-tRNA, snRNA, rRNA 
snRNA miRNA, tRNA, mt-tRNA, snoRNA, rRNA 
rRNA miRNA, tRNA, mt-tRNA, snoRNA, snRNA 
 
4.2.3. Predicting the impact of tRNA activity changes on protein translation 
Given a list of tRNAs that whose activities are predicted to increase, and the set of codons in the 
coding sequence of every human gene (obtained from Ensembl), we can assign to each gene the 
importance of that particular subset of tRNAs in its translation. First we take the reverse 
complement of each anticodon to determine approximately the set of codons it recognizes 
(ignoring post-transcriptional modifications of the anticodon sequence and non-canonical base-
pairing). Then we can compute, for each protein-coding sequence in the genome, a score 
indicating the importance of this set of anticodons to that gene’s translation (assuming no 
positional biases along the transcript in translational efficiency): 
   
∑     
  
 
where Si  is the score for sequence i, Iij  is an indicator whose value is 1 when codon j of sequence 
i is targeted by the list of given anticodons, and Ni is the length of sequence i in codons. 
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Sequences were required to be at least 50 codons long and the maximally scoring transcript 
within a gene’s set of transcripts was used as the score for that gene. 
 
4.2.4. Building a network of AD-related genes 
MicroRNA targets were taken from two databases of experimentally validated microRNA-mRNA 
interactions: mirTarBase and miRecords. Targets of the minor spliceosome were considered to 
be those genes that have U12 introns according to the database U12DB [5]. Protein-protein 
interactions were taken from the STRING tool [56]. 
 
4.3. Results 
4.3.1. Sample characteristics and RNA-seq processing statistics 
 
In order to characterize the prefrontal cortex non-coding transcriptome in AD, we performed two 
types of RNA sequencing on brain tissue from seven patients (Table 4.2). The patients were all 
non-Hispanic Caucasian females matched for age-of-death (mean 79 years vs. 79.25 years). The 
first set of libraries was generated by depleting ribosomal RNA (rRNA) from total RNA, allowing 
us to assay the expression of long non-coding and all coding transcripts independent of the 
presence of polyadenylated tails. The second set of libraries was generated by selecting for small 
RNAs (smRNA) by size fractionation, and these libraries were expected to elucidate the 
expression of, among other transcripts, short regulatory RNAs known as microRNAs. 
Table 4.2 – Summary of samples and RNA-seq data processing 
 rRNA(-) reads (millions) smRNA reads (millions) 
Dx ApoE  Age Raw  Filtered Mapped Unique Raw Trimmed Mapped 
AD ε3/ε4 81 83.6 38.3 24.1 14.1 32.5 21.3 17.3 
AD ε3/ε3 83 72.1 33.6 18.3 7.9 31.6 17.8 14.2 
AD ε3/ε4 73 73.1 32.5 19.1 8.2 25.3 15.6 11.0 
N ε3/ε3 92 59.2 27.2 15.2 9.4 26.0 12.3 8.8 
N ε2/ε3 72 81.2 32.6 18.7 11.6 30.0 13.9 11.6 
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N ε3/ε3 68 39.3 21.0 12.1 7.0 29.4 18.6 15.2 
N ε3/ε3 85 66.5 27.7 14.1 8.8 18.7 7.1 6.1 
 
4.3.2. Global changes in non-rRNA transcription in the AD brain 
The rRNA(-) libraries, as expected, were dominated by mRNAs – first exonic reads at 30% of the 
total, followed by intronic reads at 20% (Figure 4.1). Despite introns being far longer than exons, 
they were underrepresented in total RNA due to splicing; the abundance of mature mRNA versus 
pre-mRNA transcripts resulted in higher coverage of exons. The next most sequenced class of 
RNAs was mitochondrial tRNAs, containing 10-20% of the reads. Strikingly, there was a great 
degree of variability in total mt-tRNA abundance between the samples – this variability is not seen 
for any of the other types of transcripts, including nuclear tRNAs. Broadly, the data suggest that 
mt-tRNAs are slightly less abundant in the AD samples, although this difference is not statistically 
significant. This depletion of mt-tRNA transcripts in the AD samples is potentially an indicator of 
cell death in the AD-affected cells. 
Following mt-tRNA transcripts in abundance were sequences corresponding to 
transposable elements. The data suggest that transposable elements are widely expressed in this 
region of the brain, but there did not seem to be a difference between the AD and normal 
samples. The next most-sequenced class of reads consisted of those with no known annotation, 
which we call ―intergenic.‖ While 10% of these regions are  pseudogenes, it is likely that a large 
fraction of these reads are spurious mappings due to SNPs, sequencing errors, splicing, RNA 
editing, and cryptic exons or introns confounding the alignment. After intergenic reads the next 
most abundant classes were sno- and sn- (small nucleolar and small nuclear) RNAs. 
Approximately 10% of reads fell on the strand opposite to the annotated RNA and were labeled 
as ―antisense.‖ The class of RNAs showing the most antisense transcription was transposable 
elements (Figure 4.2). This antisense transcription could be indicative of antisense RNA-
mediated silencing of transposable elements in the brain transcriptome. 
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Figure 4.1- Summary of sequenced RNAs in the rRNA(-) libraries 
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Figure 4.2 – Summary of antisense transcription in the rRNA(-) libraries 
 
4.3.3. Global changes in small RNA biogenesis in the AD brain 
 
In contrast to the rRNA(-) libraries, the small RNA (smRNA) libraries were largely 
composed of microRNAs (Figure 4.3), which accounted for 60-70% of the reads. The next most 
abundant class of smRNAs were tRNA-derived fragments (tRFs), containing 10-20% of the 
reads. There was a very striking pattern in global read counts: miRNAs were overall depleted in 
the AD brain while tRFs were overall enriched. Since the next largest class, snoRNA-derived 
smRNAs, did not differ between the conditions, the data do not suggest that the apparent drop in 
overall miRNA abundance was a simple consequence of an increase in tRF abundance or that 
the apparent increase in tRF abundance was an artifact resulting from a drop in miRNA 
abundance. Interestingly, despite the difference in tRF abundance, the rRNA(-) libraries showed 
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no change in full-length tRNA transcript levels. This suggests a difference in the activity of the tRF 
biogenesis processes (e.g., tRNA cleavage) in the AD state. Increased tRNA cleavage is known 
to be an indicator of cellular stress response in eukaryotes [28,61,151]. By contrast, the inverse 
relationship was seen for mt-tRNAs: the full-length transcripts were depleted in AD, but there was 
no apparent difference in fragments derived from mt-tRNAs. This suggests that nuclear and 
mitochondrial tRNAs are perturbed by distinct mechanisms in the AD state. 
In contrast to the rRNA(-) libraries, only a very small proportion of the smRNA reads 
derived from the opposite strand to the annotated one (i.e., are antisense) (Figure 4.4). In 
general, however, the trend of the antisense smRNA reads is skewed towards repetitive elements 
similar to the rRNA(-) reads. 
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Figure 4.3 – Summary of sequenced RNAs in the smRNA-seq libraries 
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Figure 4.4 – Summary of antisense transcription in the smRNA libraries 
 
Differentially expressed transcripts in the AD brain 
Within the rRNA(-) libraries we found 215 differentially expressed RNAs, 62 of which were non-
coding. The most commonly differentially expressed non-coding RNAs were tRNAs, followed by 
lincRNAs and snoRNAs (Figure 4.5). Interestingly, while the total number of reads mapping to 
tRNAs wasn’t significantly different between the AD and normal groups, there were still many 
tRNA transcripts that were differentially expressed. We also detected 6 downregulated transcripts 
that were transcribed in a head-to-head fashion adjacent to protein-coding mRNAs (suggesting a 
bidirectional promoter), which in the literature have been termed promoter-associated RNAs 
(paRNAs) [40,74,149]. 
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Figure 4.5 – Number of differentially expressed ncRNA transcripts by RNA class 
 
Of the top 10 downregulated genes by significance, there were 5 mRNAs, 2 snoRNAs, 2 
tRNAs, and a ncRNA that is antisense to the gene STXBP5 (Table 4.3). Included among the top 
10 downregulated genes was ADCYAP1/PACAP; this gene has been shown to be 
neuroprotective in mouse models of AD via its upregulation of the alpha-secretase pathway [89]. 
Another top 10 gene, FAM190A, is a top GWAS hit for attention deficit disorder [98]. Also on the 
list was PUM2, a gene whose deficiency causes nesting behavior abnormalities in mice, a feature 
shared with mouse models of APP [54,136].The two tRNAs both code for cysteine: tRNA
Cys
GCA. 
One resides in a tandem cluster of tRNA
Cys
 on chromosome 7 and the other lies in an intron of 
the gene CPNE4 on chromosome 3, near a tandem copy of itself. 
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The top downregulated snoRNA is the C/D box snoRNA SNORD79 – it lies in an intron of 
the GAS5 gene, an ncRNA thought to function as a host for snoRNAs [138]. SNORD79 is 
predicted to guide 2'O-ribose methylation of 28S rRNA at residue A3809; therefore, its 
downregulation could negatively impact rRNA function. Similarly, the other snoRNA on the top 10 
downregulated list is the H/ACA box snoRNA SNORA36A, found on chromosome X in the intron 
of DKC1, a gene whose mutations can cause X-linked dyskeratosis congenita. Interestingly, 
DKC1 is itself a member of H/ACA box snoRNPs, and is also a member of telomerase. 
SNORA36A is predicted to guide pseudouridylation of 18S rRNA at residues U105 and U1244. 
Therefore its downregulation, like that of SNORD79, could negatively impact rRNA maturation. 
The ncRNA transcript STXBP5-AS is antisense to the gene STXBP5 which encodes for a protein 
thought to be involved in neurotransmitter release – mutations in the gene are associated with 
venous thrombosis. It is unclear what the relationship between antisense transcripts and the 
regulation of their sense-strand counterparts is. 
 
Table 4.3 – Top 10 AD-downregulated transcripts in the rRNA(-) libraries. 
Symbol UCSC id 
log2(fold 
change) P-value Description 
ADCYAP1 uc010dkh.3 -0.70 1.5E-06 
Homo sapiens adenylate cyclase 
activating polypeptide 1 (pituitary) 
TRNA_Cys uc021xee.1 -0.69 1.5E-06 tRNA Cys (anticodon GCA) 
SNORD79 uc009wwk.1 -0.67 1.2E-07 small nucleolar RNA, C/D box 79 
TRNA_Cys uc022aox.1 -0.66 7.4E-06 tRNA Cys (anticodon GCA) 
PDCD10 uc003fez.3 -0.60 2.5E-05 Programmed cell death 10 
SNORA36A uc004fmn.3 -0.58 4.4E-05 
Small nucleolar RNA, H/ACA box 
36A 
STXBP5-AS uc003qls.2 -0.56 1.7E-05 ncRNA antisense to STXBP5 
LINC00086 uc004eyv.4 -0.55 7.7E-05 lincRNA 
ANKRD30BL uc002tti.3 -0.55 1.8E-04 
Ankyrin repeat domain 30B-like 
ncRNA 
JA040723 uc022bqt.1 -0.53 1.2E-04 piRNA piR-31490 
 
In addition to the downregulated transcripts, there were also many upregulated 
transcripts (Table 4.4). Among the top 10 upregulated RNAs were 3 tRNAs, 6 mRNAs, and 1 
uncharacterized lincRNA. The tRNAs consisted of two serine-charged tRNAs (tRNA
Ser
CGA, 
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tRNA
Ser
GCU) and one tRNA
Glu
UUC. One of the tRNA
Ser
 loci lies in the promoter of B3GNT1 and the 
other lies just downstream of the circadian-rhythm-related gene PER1. Included among the 
mRNAs is that of MLXIPL, a candidate gene for genetic association with plasma triglyceride 
levels [90]. This is especially intriguing since defects in ApoE are associated with plasma 
triglyceride levels. Another top upregulated gene is CNST (cosortin) which interacts with 
connexins, a class of proteins that could be involved in AD pathogenesis pathways [92]. Yet 
another top upregulated gene, ZMYM5, is known to repress the transcription of PSEN1, one of 
the genes whose familial variants can cause AD [125]. Interestingly, two components of the minor 
spliceosome (U6atac and U12 snRNAs) are both significantly upregulated in the AD brain. The 
minor spliceosome responds positively to stress [167], and so the cell stress-related component 
of AD may play a role in its upregulation. One of the genes whose expression is modulated by the 
minor splicesome is PTEN, which can be found in NFTs in AD [141]. 
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Table 4.4 – Top 10 AD-upregulated transcripts in the rRNA(-) libraries 
Symbol UCSC id 
log2(fold 
change) 
P-
value Description 
TRNA_Ser uc021tps.1 0.85 
2.4E-
12 tRNA Ser (anticodon CGA) 
TRNA_Ser uc021qlw.1 0.78 
4.5E-
09 tRNA Ser (anticodon GCT) 
TRNA_Glu uc021vol.1 0.63 
1.7E-
06 tRNA Glu (anticodon TTC) 
TPD52L1 uc003pzu.1 0.55 
8.2E-
06 Tumor protein D52-like 1 
AK054921 uc004fbf.1 0.63 
7.7E-
06 
Highly similar to 40S 
RIBOSOMAL PROTEIN S15A. 
MLXIPL uc003tyn.1 0.66 
7.1E-
06 MLX interacting protein-like 
SPAG5 uc002hbq.3 0.55 
2.4E-
05 Sperm associated antigen 5 
TCONS_00016137 N/A 0.59 
5.7E-
05 N/A 
CNST uc001ibp.3 0.41 
6.8E-
05 
Homo sapiens consortin, 
connexin sorting protein 
ZMYM5 uc010tcn.1 0.55 
9.3E-
05 
Homo sapiens zinc finger, MYM-
type 5 (ZMYM5) 
 
4.3.4. Differentially expressed small RNAs in the AD brain 
There were a total of 456 small RNA loci differentially expressed in the human prefrontal cortex 
(Figure 4.6). The largest class of D.E. smRNAs was the intergenic class, which consists of those 
small RNA loci that don’t overlap any annotated RNA whatsoever. It is likely that a large fraction 
of these are the result of cross-mapping errors whether from SNP-induced mismatches or 
extremely high-abundance RNAs combined with the normal rate of base-calling error. 
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Figure 4.6 - Number of differentially expressed smRNA loci by ncRNA class. 
 
The next largest class was small RNAs deriving from mRNAs. It is unknown whether 
these are specifically processed from double-stranded structures on mRNAs or are simple mRNA 
fragments resulting from exonuclease activity on degrading transcripts. Since 60% of these 
mRNA-derived smRNA loci had lengths shorter than 50nt, it is likely that the class is a mix of the 
two: small, well defined loci and larger loci that are home to a larger number of more varied 
cleavage events. This proportion (60%) was not different between upregulated and 
downregulated mRNA-derived smRNA loci. Interesting members of the list include APOD, genetic 
variants in which are associated with AD in Chinese and Japanese populations [29,135]. GLRX2, 
glutaredoxin 2, is a mitochondrial protein involved in protection against oxidative stress in 
mitochondria. SCD5, involved in fatty acid metabolism [7], has been shown to be upregulated in 
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the AD brain. SPP1, or osteopontin, is a gene whose protein product is a biomarker for mild 
cognitive impairment [147] and AD. SQSTM1 has been shown to be overexpressed in the AD 
brain, and it also associates with the neurofibrillary tangles (NFTs) characteristic of AD [121]. 
CRYAB (Alpha-b crystallin) associates with NFTs as well [109]. CLSTN1 (calsyntenin I) has been 
shown to regulate amyloid beta production [157]. 
Table 4.5 – Differentially expressed small RNAs derived from mRNAs or antisense transcripts 
Type Gene Locus log2(FC) FDR 
mRNA exon CLDN12 chr7:90044707-90044724(+) -1.91 0.02 
Antisense mRNA ENTPD4 chr8:23315089-23315113(+) 1.89 0.03 
Antisense mRNA ADAD1 chr4:123332506-123332525(+) -2.08 0.04 
mRNA exon KIF5C chr2:149829885-149829908(+) 1.76 0.05 
mRNA exon UHMK1 chr1:162470009-162470034(+) 1.95 0.06 
mRNA exon TOB1 chr17:48943684-48943732(-) -1.64 0.07 
Antisense mRNA BEND6 chr6:56820040-56820056(-) -1.47 0.07 
mRNA exon MAP2 chr2:210543331-210543381(+) 1.41 0.08 
mRNA exon KCNMA1 chr10:78629571-78629589(-) 1.86 0.08 
mRNA exon NEFH chr22:29885590-29885903(+) 1.71 0.08 
Antisense mRNA C1GALT1C1 chrX:119760650-119760667(-) -1.28 0.08 
mRNA exon GLRX2 chr1:193074487-193074511(-) -1.59 0.10 
mRNA exon MEF2C chr5:88014477-88014502(-) 1.16 0.10 
mRNA exon NEFH chr22:29885387-29885507(+) 1.53 0.10 
Antisense mRNA ATM chr11:108161209-108161226(+) 1.20 0.11 
mRNA exon SCD5 chr4:83550834-83550935(-) 1.51 0.12 
Antisense mRNA CD163 chr12:7651550-7651659(-) 1.61 0.12 
mRNA exon SPP1 chr4:88903663-88904132(+) 1.46 0.12 
mRNA exon TMEM123 chr11:102268541-102268559(-) 1.20 0.12 
mRNA exon WDR82 chr3:52290206-52290229(-) 1.29 0.12 
Antisense mRNA B2M chr15:45007645-45007842(+) 1.28 0.12 
mRNA exon KCTD16 chr5:143586444-143586466(+) 1.38 0.12 
mRNA exon SQSTM1 chr5:179264066-179264095(+) 1.23 0.12 
mRNA exon QDPR chr4:17503379-17503480(-) 1.23 0.12 
mRNA exon MAN1A2 chr1:117957358-117957443(+) 1.28 0.13 
mRNA exon EIF4G3 chr1:21268544-21268587(-) 1.22 0.14 
mRNA exon SLC17A7 chr19:49936063-49936090(-) 1.20 0.14 
mRNA exon PDZD2 chr5:32087421-32087437(+) 1.31 0.15 
mRNA exon SON chr21:34949108-34949132(+) 1.25 0.15 
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Antisense mRNA SEC16B chr1:177929373-177929391(+) -1.38 0.15 
mRNA exon GLUL chr1:182353819-182353853(-) 1.37 0.16 
Antisense mRNA TTLL6 chr17:46840131-46840146(+) -1.17 0.16 
mRNA exon CRYAB chr11:111779396-111779441(-) 1.11 0.16 
mRNA exon KDR chr4:55945467-55945483(-) 1.22 0.16 
mRNA exon NHP2 chr5:177576651-177576675(-) 1.07 0.16 
mRNA exon DLG2 chr11:83170812-83170846(-) 1.19 0.17 
mRNA exon ENC1 chr5:73923655-73923709(-) -1.35 0.17 
mRNA exon CNTN1 chr12:41331379-41331447(+) -1.34 0.17 
Antisense mRNA ICA1 chr7:8167738-8167756(+) 1.19 0.17 
mRNA exon CPE chr4:166408644-166408696(+) -1.17 0.17 
mRNA exon NECAP1 chr12:8242814-8242849(+) -1.36 0.18 
mRNA exon LAP3 chr4:17609300-17609343(+) 1.32 0.18 
mRNA exon DNAJC6 chr1:65880026-65880103(+) 1.15 0.18 
mRNA exon FTH1 chr11:61735039-61735097(-) 1.24 0.21 
mRNA exon PSD3 chr8:18393376-18393440(-) 1.07 0.21 
mRNA exon SYNE1 chr6:152647191-152647214(-) 1.19 0.21 
Antisense mRNA ZMYM5 chr13:20425915-20425933(+) -1.25 0.21 
Antisense mRNA NIPAL3 chr1:24746024-24746043(-) -1.20 0.22 
mRNA exon RPL30 chr8:99057206-99057270(-) 0.95 0.22 
mRNA exon GNAS chr20:57478778-57478839(+) -1.02 0.22 
mRNA exon SRCIN1 chr17:36708098-36708114(-) 1.03 0.22 
mRNA exon MAP1B chr5:71493868-71493952(+) 1.02 0.22 
mRNA exon OSGIN1 chr16:83994344-83994359(+) 1.23 0.22 
mRNA exon CLSTN1 chr1:9811636-9811688(-) 0.76 0.22 
mRNA exon SPOCK2 chr10:73827391-73827428(-) -1.18 0.22 
Antisense mRNA WRAP73 chr1:3564083-3564098(+) -1.00 0.23 
Antisense mRNA APOD chr3:195300738-195300842(-) 0.93 0.25 
mRNA exon CPE chr4:166418676-166418744(+) -1.14 0.25 
 
Similarly to the mRNA-derived smRNAs, snoRNA-derived smRNAs tended to be 
upregulated rather than downregulated in the AD-affected samples (Table 4.6). Interestingly, 
these transcripts largely did not overlap with the transcripts that were differentially expressed in 
the rRNA(-) libraries. The only snoRNA showing changes in both libraries was SNORA18, with 
both the full-length transcripts and the small RNA products being upregulated in AD. SNORA18 is 
an ―orphan‖ snoRNA – that is, its target RNA is unknown.   
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Table 4.6 – Differentially expressed snoRNAs in rRNA(-) and smRNA libraries 
Transcript Log2(fold change) Predicted target 
 
rRNA(-) smRNA 
 SCARNA16 
 
0.92 Pseudouridylation of U1 snRNA U5 
SNORA18 0.43 1.1 Unknown 
SNORA26 0.39 
 
2'O-ribose methylation of 28S rRNA A389  
SNORA31 
 
-1.44 Pseudouridylation of 28S rRNA U3713 & 18S U218 
SNORA36A -0.58
 
Pseudouridylation of 18S rRNA U105, U1244 
SNORA53 
 
0.91 Unknown 
SNORA5A 
 
0.91 Pseudouridylation of 18S rRNA U1625, U1238 
SNORA65 
 
0.84 Pseudouridylation of 28S rRNA U4373, U4427 
SNORA68 0.35
 
Pseudouridylation of 28S rRNA U4393 
SNORA77 0.45 
 
Pseudouridylation of 18S rRNA U814 
SNORD11 
 
0.93 2'O-ribose methylation of 18S rRNA G509 
SNORD115-39 0.42
 
5HT-2C mRNA 
SNORD115-40 0.43 
 
5HT-2C mRNA 
SNORD115-48 
 
-0.93 5HT-2C mRNA 
SNORD117 
 
0.64 Unknown 
SNORD121B 
 
0.89 2'O-ribose methylation of 28S rRNA G4607 
SNORD15B 
 
-1.15 2'O-ribose methylation of 28S rRNA A3764 
SNORD36B 
 
0.64 2'O-ribose methylation of 18S rRNA A668 
SNORD36C 
 
0.67 2'O-ribose methylation of 28S rRNA A3703 
SNORD4B 
 
-1.02 2'O-ribose methylation of 18S rRNA U121 
SNORD60 
 
0.91 2'O-ribose methylation of 28S rRNA G4340 
SNORD73A 
 
0.69 2'O-ribose methylation of 28S rRNA G1747 
SNORD79 -0.67
 
2'O-ribose methylation of 28S rRNA A3809 
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 Several microRNAs were differentially expressed in the smRNA libraries (Table 4.7). 
Downregulation of mir-132 has been shown to be implicated in derepression of FOXO3 and thus 
promote neuronal apoptosis in AD [160]. The totality of predicted targets of these miRs is given in 
Table 4.8. 
 
Table 4.7 – Differentially expressed microRNAs. 
microRNA log2(Fold change) False discovery rate 
mir-412 -1.71 0.064 
mir-886 1.41 0.102 
mir-4326 1.50 0.115 
mir-381 0.78 0.116 
mir-889 0.85 0.121 
mir-877 -0.88 0.159 
mir-96 -1.05 0.162 
mir-132 -0.76 0.162 
mir-95 0.65 0.178 
mir-26a-2 0.58 0.211 
mir-556 -0.99 0.214 
mir-425 -0.57 0.223 
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Table 4.8 – Experimentally validated targets of the D.E. miRNAs. 
microRNA Target gene Description 
miR-132 ARHGAP32 Rho GTPase-activating protein 
miR-132 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
miR-132 RFX4 regulatory factor X, 4 (influences HLA class II expression) 
miR-132 SIRT1 sirtuin (silent mating type information regulation 2 homolog)  
mir-26a CHFR checkpoint with forkhead and ring finger domains 
mir-26a EZH2 enhancer of zeste homolog 2 (Drosophila) 
mir-26a PLAG1 pleiomorphic adenoma gene 1 
mir-26a PTP4A1 protein tyrosine phosphatase type IVA, member 1 
mir-26a SMAD1 SMAD family member 1 
mir-26a STRADB STE20-related kinase adapter protein beta 
mir-26a TAF12 
TAF12 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 20kDa 
mir-26a TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 
miR-381 LRRC4 leucine rich repeat containing 4 
miR-412 ACVR1C activin A receptor, type IC 
miR-877 EFNA5 ephrin-A5 
miR-877 ELF1 E74-like factor 1 (ets domain transcription factor) 
miR-877 FXR2 fragile X mental retardation, autosomal homolog 2 
miR-877 SCN3A sodium channel, voltage-gated, type III, alpha subunit 
miR-877 SMG5 Smg-5 homolog, nonsense mediated mRNA decay  
miR-877 TP53INP2 tumor protein p53 inducible nuclear protein 2 
miR-95 SNX1 sorting nexin 1 
miR-96 ADCY6 adenylate cyclase 6 
miR-96 AQP5 aquaporin 5 
miR-96 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
miR-96 CELSR2 
cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo 
homolog, Drosophila) 
miR-96 FOXO1 forkhead box O1 
miR-96 FOXO3 forkhead box O3; forkhead box O3B pseudogene 
miR-96 HTR1B 5-hydroxytryptamine (serotonin) receptor 1B 
miR-96 IRS1 insulin receptor substrate 1 
miR-96 KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
miR-96 MITF microphthalmia-associated transcription factor 
miR-96 MYRIP myosin VIIA and Rab interacting protein 
miR-96 NR3C1 
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor) 
miR-96 ODF2 outer dense fiber of sperm tails 2 
miR-96 PRMT5 protein arginine methyltransferase 5 
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4.3.5. tRNAs are differentially expressed and processed in the AD brain 
Several tRNAs, both nuclear and mitochondrial, were differentially expressed in the AD brain. In 
addition, we found that tRNAs also tended to be differentially processed – that is, the cleavage of 
tRNAs into small RNAs known as tRNA fragments, or tRFs, changes in the AD brain (Table 4.9, 
Table 4.10). Differential expression in the rRNA(-) libraries indicates differences in the abundance 
of the long tRNA transcript, whereas differential expression in the smRNA libraries indicates 
differential processing of the tRNA into tRNA fragments. With the exception of one tRF deriving 
from a pseudogenic tRNA on chr1, all the tRNA-associated small RNAs were strongly 
upregulated in AD. This potentially corresponds to a decrease in the activity and/or increase in 
cleavage of these tRNAs. In addition to the fragments, many tRNA transcripts themselves were 
downregulated, including most prominently tRNA
Cys
GCA and the mitochondrial mt-tRNA
Pro
UGG. Only 
in one case did we observe changes in both the tRNA transcript and its fragments: tRNA
Lys
UUU 
shows upregulation of both. Interestingly, tRNA-associated small RNAs, mRNA-associated small 
RNAs, and snoRNA-associated small RNAs were the only overall-upregulated classes of small 
RNAs in AD.  
miR-96 RYK RYK receptor-like tyrosine kinase 
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Table 4.9 – Downregulated tRNAs and tRNA fragments in the AD brain with expression fold-changes. 
Transcript Locus log2(FC) p-value 
tRFΨGUC chr1:161492987(+) -1.08 1.5E-02 
tRNACysGCA chr3:131947943(-) -0.67 1.5E-06 
tRNACysGCA chr7:149007280(+) -0.64 7.2E-06 
mt-tRNAProUGG chrM:15954(-) -0.50 1.4E-04 
tRNAArgCCG chr6:28849164(+) -0.49 3.8E-04 
tRNATyrGUA chr14:21121257(-) -0.45 1.2E-03 
tRNAValAAC chr6:27618706(-) -0.45 1.4E-03 
tRNAArgUCG chr6:26299904(+) -0.44 1.8E-03 
tRNATyrGUA chr14:21131350(-) -0.43 2.2E-03 
tRNAArgCCU chr17:73030525(-) -0.43 1.9E-03 
tRNAArgUCG chr6:26323045(+) -0.39 4.1E-03 
tRNACysGCA chr15:80036996(+) -0.39 5.0E-03 
tRNAValCAC chr6:27248048(-) -0.32 3.6E-03 
 
Table 4.10 – Upregulated tRNAs and tRNA fragments in the AD brain with expression fold-changes. 
Transcript Locus log2(FC) p-value 
tRFThrAGU chr17:8090478(+) 1.55 8.8E-04 
tRFIleAAU chr6:27205343(-) 1.50 5.0E-03 
tRFLysUUU chr17:8022468(+) 1.35 1.7E-03 
tRFΨUGC chr6:28601911(-) 1.32 2.2E-02 
tRFMetCAU chr8:124169459(-) 1.27 8.3E-03 
tRFAsnGUU chr1:148248113(+) 1.19 1.6E-02 
tRFAlaUGC chr11:50233925(-) 1.18 9.6E-03 
tRFThrUGU chr6:28442320(-) 1.06 2.7E-03 
tRFAlaCGC chr2:157257280(+) 1.03 6.6E-03 
tRFPheGAA chr12:125412379(-) 0.96 7.5E-03 
tRFΨAGG chr16:3202636(-) 0.86 2.0E-02 
tRNASerCGA chr17:8042198(-) 0.84 2.0E-12 
tRFGlnCUG chr15:66161389(-) 0.81 2.3E-02 
tRNASerGCU chr11:66115590(+) 0.78 2.2E-09 
tRFGluUUC chr13:45491997(-) 0.76 2.8E-02 
mt-tRNAAspGUC chrM:7516(+) 0.72 9.0E-08 
tRNAGluUUC chr2:131094700(-) 0.63 1.4E-06 
tRNALysUUU chr17:8022472(+) 0.50 3.9E-04 
tRNALysCUU chr5:180634754(+) 0.44 2.0E-03 
tRNATrpCCA chr6:26331671(-) 0.39 4.6E-03 
tRNAAspGUC chr12:96429798(+) 0.39 2.5E-03 
tRNAAlaUGC chr12:125424511(+) 0.37 3.5E-03 
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While it is unclear what the global effects of these changes in tRNA expression and 
processing are, we can start by predicting their effect on the translation of specific mRNAs into 
proteins by finding those mRNAs which, by virtue of their coding sequences, would be most 
affected if the tRNAs with corresponding anticodons were perturbed. In order to separate the sets 
of anticodons into those whose associated tRNAs decrease in activity and those whose tRNAs 
increase in activity, we make a few assumptions about the nature of the expression changes in 
tRNAs and their associated fragments. We assume that increase of the cleavage process 
corresponds to an inhibition of tRNA activity, and so can combine the upregulated tRFs with the 
downregulated tRNAs into a set of tRNAs, and thus anticodons, whose activity is downregulated. 
Conversely, those tRNAs that are upregulated or whose concomitant fragments are 
downregulated can be presumed to be increasing in activity. Given the sets of anticodons that are 
uptranslated and those that are downtranslated, we can score each gene by taking the proportion 
of its codons that are complementary to any of the anticodons in each of the two lists. 
Furthermore, we limit the set of genes to those having at least one count in the brain whole 
transcriptome RNA-seq dataset (Table 4.11, Table 4.12.). 
Table 4.11 – Top 10 brain-expressed genes predicted to be down-translated due to tRNA changes. 
Gene Description Anticodon 
score 
Num. 
codons 
SRP14 Signal recognition particle 14kDa  0.198 171 
PRKCG Protein kinase C, gamma 0.190 58 
VOPP1 Vesicular, overexpressed in cancer, prosurvival protein 1 0.185 65 
TMEM123 Transmembrane protein  123 0.182 66 
EPN2 Epsin 2 0.180 61 
MLH1 MutL homolog 1 0.179 117 
FAM3A Family with sequence similarity 3, member A 0.175 63 
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 0.174 144 
GALNT13 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 0.172 58 
LRRCC1 Leucine rich repeat and coiled-coil domain containing 1 0.171 111 
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Table 4.12 - Top 10 brain-expressed genes predicted to be up-translated due to tRNA changes. 
Gene Description Anticodon 
score 
Num. 
codons 
RPS25 Ribosomal protein S25 0.183 120 
SRP14 Signal recognition particle 14kDa 0.164 171 
RERE Arginine-glutamic acid dipeptide (RE) repeats 0.162 105 
RAI14 Retinoic acid induced 14 0.159 63 
HMGN5 High mobility group nucleosome binding domain 5 0.148 603 
SREK1IP1 SREK1-interacting protein 1 0.145 468 
RSRC2 Arginine/serine-rich coiled-coil 2 0.143 77 
CCDC91 Coiled-coil domain containing 91 0.142 380 
ARGLU1 Arginine and glutamate rich 1 0.141 206 
DMD Dystrophin (DMD) 0.138 123 
 
 In order to assess the biological significance of these sets of genes, we look for 
enrichment of particular biological pathways in the top 1,000 genes by codon-score. Strikingly, 
the list of putatively down-translated genes is enriched for KEGG pathways that correspond to 
several neurodegenerative disorders, including Alzheimer’s disease (Table 4.13). While this 
enrichment is largely a result of the presence in the list of mitochondrial Complex I genes, the list 
also includes several genes thought to be highly significant in AD pathogenesis: ADAM10 (alpha 
secretase), BACE1 (beta-secretase), SNCA (synuclein alpha), TF (transferrin), and PICALM. 
Table 4.13 – KEGG pathways enriched for putative down-translated genes 
KEGG Pathway Adjusted p-value 
Ribosome 0.0002 
Oxidative phosphorylation 0.0017 
Huntington’s disease 0.0017 
Alzheimer’s disease 0.0062 
Vasopressin-regulated water reabsorption   0.0062 
Parkinson’s disease 0.0102 
Glycosphingolipid biosynthesis - ganglio series 0.0103 
Glycosaminoglycan biosynthesis - chondroitin sulfate 0.0103 
Epithelial cell signaling in Helicobacter pylori infection 0.0103 
Lysosome 0.0127 
 
4.3.6. Functional characterization of the differentially expressed transcripts 
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We combined the rRNA(-) and smRNA libraries into a list of genes based on differential 
expression of transcripts, of smRNA loci, and of microRNAs (by including their targets). 
microRNA target predictions were taken from three sources. The first is StarBase [165], which 
uses Argonaute CLIP-seq data to locate candidate miRNA target sites and then uses sequence-
based prediction tools to associate microRNAs. We also included all experimentally validated 
predictions compiled within the mirTarBase and miRecord databases [80,164]. When a microRNA 
went up in expression in AD, we considered its targets as going down (repressed) and vice versa. 
We also included genes associated with ncRNAs found to be D.E. in the rRNA(-) libraries; for 
example, if an antisense transcript was D.E. then we included the sense transcript in the list. 
Notable observations relevant to AD pathology include downregulation of genes involved in 
cytoskeleton organization (DLC1, LIMA1, CEP76, RAC1, MAP4, TMSB4X, RICTOR, DST, 
CTNNB1) and nuclear localization (KPNA3, KPNB1, TNPO1). Notable among the upregulated 
categories are TGF-beta signaling genes (MAPK1, ACVR2B, E2F5, SMAD7, PPP2CB, SMAD5, 
RBL1, SMAD2, THBS3, ACVR1C, ACVR1), dysfunction of which has been implicated in AD [39]. 
In addition, apoptotic genes (MEF2C, PRKCZ, TMX1, ZAK, XIAP, STAT5B, MITF, CBX4, SOX4, 
FOXO1, EIF5A, FOXO3, STK17A, ITM2B, MST4, ACVR1C, PEA15, IGF1R, G2E3, MAP3K5, 
KRAS, SQSTM1, BCL11B, PPP2CB, RASA1, DHCR24, KCNMA1, SPPL3, BCL10, SGK3) are 
thought to be critical in AD pathogenesis and indeed appear to be upregulated in these data. 
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Table 4.14 - Top downregulated functional categories in AD. 
Category P-value 
GO:0003714~transcription corepressor activity 1.8E-05 
GO:0048598~embryonic morphogenesis 1.6E-04 
hsa03040:Spliceosome 1.7E-02 
GO:0001657~ureteric bud development 7.1E-03 
GO:0016477~cell migration 3.3E-03 
GO:0009967~positive regulation of signal transduction 5.9E-03 
GO:0048568~embryonic organ development 4.8E-03 
GO:0008139~nuclear localization sequence binding 9.4E-03 
GO:0030522~intracellular receptor-mediated signaling pathway 6.1E-03 
GO:0007049~cell cycle 1.2E-02 
GO:0051493~regulation of cytoskeleton organization 1.0E-02 
GO:0051056~regulation of small GTPase mediated signal transduction 1.0E-02 
GO:0000059~protein import into nucleus, docking 5.7E-03 
GO:0007584~response to nutrient 1.2E-02 
 
 
 
Table 4.15 - Top upregulated functional categories in AD. 
Category P-value 
GO:0016563~transcription activator activity 4.7E-03 
GO:0030323~respiratory tube development 2.6E-05 
GO:0042981~regulation of apoptosis 2.6E-06 
GO:0019901~protein kinase binding 2.5E-03 
GO:0045934~negative regulation of nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process 1.1E-03 
GO:0003714~transcription corepressor activity 6.8E-03 
GO:0001944~vasculature development 6.8E-04 
GO:0035295~tube development 3.5E-06 
GO:0000226~microtubule cytoskeleton organization 8.1E-03 
GO:0001784~phosphotyrosine binding 1.4E-02 
GO:0016568~chromatin modification 4.4E-03 
GO:0048598~embryonic morphogenesis 5.7E-03 
hsa04350:TGF-beta signaling pathway 2.2E-04 
GO:0004674~protein serine/threonine kinase activity 8.2E-04 
GO:0001843~neural tube closure 9.2E-03 
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4.3.7. Building an integrative network 
While expression data can inform us about associations between disease state and regulatory 
changes, their impact can be greatly increased by integrating such findings with genetics data. 
The recent influx in genetics results for Alzheimer’s disease, along with burgeoning 
pathway/interaction datasets, allows us to link functional correlations with potentially causal 
factors in an unprecedented fashion. Here we present a network of genes that has been ―seeded‖ 
by known genetic factors in AD, as well as the MAPT (tau) gene which is a key factor in the 
formation of the NFTs (Figure 4.7). It should be noted that while MAPT is not known to be a 
genetic factor in AD, AD is considered by many pathologists to be a tauopathy due to the 
hallmark involvement of NFTs. In addition, we have included all of the genes whose protein 
products are directly involved in the processing of APP: PSEN1, PSEN2, PSENEN, NCSTN, 
APH1A, APH1B (gamma-secretase), BACE1, BACE2 (beta-secretase), and ADAM10 (alpha-
secretase). In addition to protein-protein interactions, we have also included microRNA-target 
interactions, the interaction between ZMYM5 and the promoter of PSEN1, interactions between 
gamma secretase components and APP, and interactions between SNORD115 loci and the 
HTR2C gene. MicroRNAs mir-132, mir-96, and mir-26a appear to be highly-connected within this 
network, as well as SIRT1, SDC4, SNRPF. SIRT1 is an aging-associated gene and has been 
found to be neuroprotective against Abeta toxicity and NFT formation in mouse brains [44]. SDC4 
(syndecan-4) is involved in the healing process, and its downregulation in AD may indicate an 
impaired ability to recover from the damage inflicted during AD pathology [47]. 
Red elements were upregulated and blue elements were downregulated; triangles are 
miRNAs, circles are full transcripts, and squares are smRNA loci derived from mRNAs. 
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Figure 4.7 – An integrative network of AD. 
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4.4. Discussion 
In the Alzheimer’s disease state we observe several global changes in the expression of non-
coding RNAs. The most striking change is that of tRNAs and a recently discovered class of RNAs 
comprised of tRNA fragments (tRFs). By comparing the anticodons associated with the tRNAs 
with the coding sequences of the human genome, we have presented a list of genes most likely 
to be translationally perturbed by the changes in tRNA expression. Enriched among this set of 
genes are Complex I members, implicating an association between tRNA dysregulation, 
mitochondrial function, and Alzheimer’s disease. While the mitochondrial cascade hypothesis is a 
longstanding theory in the AD field [148], its connection to tRNAs remains largely unexplored. 
Another, independent, piece of evidence suggesting mitochondrial involvement in AD is the 
transcriptional downregulation of the mitochondrially encoded gene NADH dehydrogenase 6, yet 
another member of Complex I. In addition to perturbations to Complex I function, we also observe 
an overall decrease in mitochondrial tRNA expression. While we also see perturbations to other 
genes known to be involved in AD (particularly those involved in amyloid beta metabolism and 
related genes), our data lend great weight to the mitochondrial cascade hypothesis as an 
important avenue of research in AD. Another interesting gene with a high likelihood of 
translational changes given the tRNA changes is the signal recognition particle gene SRP14. The 
SRP is a ribonucleotide complex composed of the 7SL non-coding RNA as well as several 
proteins, including SRP14. This complex is responsible for targeting proteins to the endoplasmic 
reticulum (ER). This provides another potential piece of evidence that ER stress is associated 
with the pathology of AD, a theory that has recently gained traction [156]. 
By performing non-traditional RNA-sequencing we are able to elucidate the transcriptome 
of the AD brain in novel ways. The addition of non-coding RNAs, particularly those that modify 
other RNAs, helps to induce directionality to the characterization of genes associated with the 
disease state. As opposed to producing a simple set of correlations of gene expression amongst 
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an incohesive group of genes, we can now begin to generate hypotheses based on annotated 
regulatory connections. For example, the inclusion of microRNAs provides a ―flow‖ to the network 
where microRNAs are upstream of their targets. The addition of genetically-associated loci can 
also provide a hint of causality where gene expression alone fails to do so. The field of genomics 
benefits the most when the cycle of hypothesis generating studies and functional studies flows 
continuously; here I have demonstrated that insights learned from small-scale functional studies 
can be fed back into a higher-throughput correlational study in order to sharpen its impact. 
 
5. Conclusion 
In this dissertation I have presented several methods for analyzing the non-coding transcriptome 
and an application of such studies to a disease: namely, Alzheimer’s disease. Given the 
longstanding prejudice against it in gene expression studies, the non-coding transcriptome is a 
treasure trove of unmined biological insights. By moving beyond simple assays of differential 
expression of protein-coding mRNAs we can finally begin to elucidate many previously neglected 
facets of the transcriptome. 
In Chapter 2 I presented a method for examining noncanonical nucleotides in non-coding 
RNAs. Non-canonical nucleotides are just now coming of age in the field of epigenetics (DNA 
methylation and hydroxymethylation in particular), but the field of epitranscriptomics is only just 
beginning to be appreciated. These modified nucleotides are already established as biomarkers 
in some cancers [42,131,146] – but their incorporation into actual transcripts has yet to be studied 
in many disease systems. Ongoing work in the next several years will likely focus on the 
differences in incorporation of these modifications between disease and affected states, as well 
as across tissue types and even in evolutionary studies across species. 
108 
 
In Chapter 3 I described a method for characterizing small non-coding RNAs using a 
robust model that works both within and across a variety of tissue types. By beginning to describe 
the uncharacterized portion of the transcriptome we can begin to apply it to medicine – the most 
likely application of such basic biology is in the field of diagnostic biomarkers. Currently 
dominated by protein-based biomarkers, nucleotide-based biomarkers are likely to play a 
significant role in the coming years due to their greater easy of handling, greater reproducibility, 
and their pliability to large-scale molecular biology techniques. 
In Chapter 4 I showcased a study of the non-coding transcriptome in Alzheimer’s 
disease. By combining heretofore-uncharacterized non-coding changes in the AD transcriptome 
with known genetically associated loci, I was able to build a network that connected seemingly 
distant regions of the correlational-gene-expression network. Furthermore, the inclusion of 
regulatory RNAs like microRNAs and the differentially expressed minor spliceosome create an 
unprecedented opportunity for generating clearer directional hypotheses from gene expression 
data. Finally, the changes I describe in tRNA expression preferentially affect genes implicated in 
mitochondrial function, lending weight to the mitochondrial cascade hypothesis in AD. 
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